Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer

Colorectal cancer is a sporadic, hereditary, or familial based disease in its origin, caused due to diverse set of mutations in large intestinal epithelial cells. Colorectal cancer (CRC) is a common and deadly disease that accounts for the 4^th worldwide highly variable malignancy. For the early detection of CRC, the most common predictive biomarker found endogenously are KRAS and ctDNA/cfDNA along with SEPT9 methylated DNA. Early detection and screening for CRC are necessary and multiple methods can be employed to screen and perform early diagnosis of CRC. Colonoscopy, an invasive method is most prevalent for diagnosing CRC or confirming the positive result as compared to other screening methods whereas several non-invasive techniques such as molecular analysis of breath, urine, blood, and stool can also be performed for early detection. Interestingly, widely used medicines known as non-steroidal anti-inflammatory drugs (NSAIDs) to reduce pain and inflammation have reported chemopreventive impact on gastrointestinal malignancies, especially CRC in several epidemiological and preclinical types of research. NSAID acts by inhibiting two cyclooxygenase enzymes, thereby preventing the synthesis of prostaglandins (PGs) and causing NSAID-induced apoptosis and growth inhibition in CRC cells. This review paper majorly focuses on the diversity of natural and synthetic biomarkers and various techniques for the early detection of CRC. An approach toward current advancement in CRC detection techniques and the role of NSAIDs in CRC chemoprevention has been explored systematically. Several prominent governing mechanisms of the anti-cancer effects of NSAIDs and their synergistic effect with statins for an effective chemopreventive measure have also been discussed in this review paper.

1. Introduction

Colorectal cancer remains one of the fourth most common malignancies worldwide after lung, liver, and stomach cancer. It majorly develops after the age of 50 whereas, a dramatic increase in the younger generation has been observed with an expected increase rate of 140% by the year 2030. A significant disparity in the incidence and survival rates of CRC between developed and developing countries depicts a difference in socioeconomic development (1).Genetic inheritance has been proved to play an important role in the development of CRC, with men being the major targets. Apart from genetic predisposition, lifestyle factors such as inactivity, type-2 diabetes mellitus (TDM), alcohol consumption, smoking, and obesity also influence the risk of CRC (2). Familial adenomatous polyposis and lynch syndrome are the two most prominent inherited syndromes that account for approximately 5% of all CRC. The accumulation of genetic mutations results in the transformation of normal colonic epithelium to a precancerous lesion and ultimately to invasive carcinoma over 10-15 years. Whereas people having adenomatous polyps or polyps with villous or tubulovillous dysplasia are at higher risk of developing synchronous and metachronous CRC primary cancer. Unfortunately, people who survived cancer at a childhood age and received abdominal radiation are at higher risk of developing CRC thus, it is recommended to adopt a screening session after 10 years or at the age of 35 (3). Hence, the early detection and removal of preformed or developing polyps will eliminate the chances of CRC. Polyps which are hamartomatous and serrated have also proven to be responsible for leading to CRC. The molecular pathways such as chromosomal instability, mismatch repair and hypermethylation has been attributed to the major pathways linked to CRC (4). Adenocarcinomas accounts for more than 90% of CRC whereas adenosquamous, spindle, squamous and undifferentiated are frequently not seen. Among the treatments for CRC, surgical resection is commonly adopted for localized non-metastatic stage CRC. Additionally, palliative systemic chemotherapy and the use of NSAIDs as chemoprevention are offered to non-surgical candidates and may prove to be a curative option (5).

Surgical removal of polyps and increasing death of CRC requires the demand of risk assessment, screening, differential diagnosis, prognosis determination, treatment response prediction, and disease progression monitoring. These potentialities are determined with the help of biomarkers in oncology. Biomarkers help in biological observation, which ideally predicts the endpoint or intermediate outcome of a disease at an early stage where it is difficult to be observed (6). Biomarkers must undergo a thorough evaluation, including analytical validation, clinical validation, and assessment of clinical utility, before being incorporated into routine clinical care because of the crucial role they play at all stages of the disease (7). In CRC treatment biomarkers, molecular pattern act as a tool for the early detection of colorectal cancer. These biomarkers play an important role in the early detection and well-individualized treatment of people suffering from cancer. The various categories of biomarkers are predictive, prognosis, and diagnostic which help to determine the progression and recurrence of cancer whereas, it also proves to be an effective therapeutic target (8). The detail view of various biomarkers along with their potentiality in CRC has been mentioned systematically in the next section.

After an early detection of CRC, the intervention of therapeutics to curb the progression of colorectal cancer becomes an important task. Hence, NSAIDs are believed to have a chemopreventive impact on gastrointestinal malignancies, and more especially, on colorectal cancer, according to a significant body of data from epidemiological and preclinical research (9). Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of chemical compounds that are typically unrelated yet have some therapeutic qualities and side effects. They are among the most widely used medicines in the world and have potent analgesic, antipyretic, and anti-inflammatory properties (10). NSAIDs are among the most widely used medications, supporting their inclusion on the WHO’s Model List of Essential Medicines due to their effectiveness in lowering pain and inflammation (11). They primarily work by inhibiting two cyclooxygenase enzymes, which stop the production of prostaglandins (PGs). Numerous cellular activities, including gastrointestinal cytoprotection, hemostasis and thrombosis, inflammation, renal hemodynamics, cartilage turnover, and angiogenesis, depend heavily on PGs. A lot of different illnesses’ pathophysiologies are heavily influenced by inflammation. PGs, coagulation cascade-derived peptides, interleukin IL-2, IL-6, and tumor necrosis factor (TNF) are among the inflammatory mediators whose production and activity are affected by NSAIDs (12). Long-term use of NSAIDs has also been linked to renal illness, which can cause both acute and chronic abnormalities in kidney function (13). The US Food and Drug Administration (FDA) was led by these consequences to issue a scientific statement in 2005 that emphasized, “the necessity of utilizing the lowest effective dose for the shortest time feasible if therapy with an NSAID is necessary for an individual patient” (14).

2. Biomarkers

According to the National Cancer Institute, a biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal activity, as well as of a condition or disease, such as cancer (NCI). A patient with the condition can frequently be distinguished from a healthy person using biomarkers. The adjustments could be brought on by post-translational modifications, somatic or germline mutations, transcriptional changes, or other factors. Proteins (such as an enzyme or receptor), nucleic acids (such as a microRNA or other non-coding RNA), antibodies, and peptides are only a few examples of the wide variety of biomarkers. A few examples of the kinds of alterations that can be regarded biomarkers are changes in gene expression, proteomic signatures, and metabolomic signatures. In order to be analyzed non-invasively and serially, biomarkers can be detected in the circulation (whole blood, serum, or plasma), excretions or secretions (stool, urine, sputum, or nipple discharge), or they may be formed from tissues, necessitating a biopsy or specialized imaging. Sequence variations in germ-line DNA recovered from whole blood, sputum, or buccal cells are examples of inherited genetic biomarkers. Mutations in DNA extracted from tumor tissue are examples of somatic genetic biomarkers (8). Briefly tabulated certain biomarkers and their significance in various type of cancer in Table 1. Prostate-specific antigen (PSA) is a frequently employed but contentious biomarker for screening (22). Biomarkers can be used to assess a patient’s prognosis, or the likelihood of the disease returning without regard to treatment, after a cancer diagnosis. More lately, the prognosis for specific malignancies is being determined using modern methods. Additionally, biomarkers can be used to modify the response to a particular therapy, or as “predictive factors,” or to determine which therapy is most likely to be successful. Because somatic mutations in KRAS are linked to poor response to anti-epidermal growth factor receptor (EGFR) focused therapy, KRAS is a predictive biomarker for colorectal cancer (23).

TABLE 1

Table 1. Biomarkers and their significance in various type of cancers.

Overexpression of the estrogen receptor in breast cancer predicts sensitivity to anti-endocrine therapy like tamoxifen (24) whereas overexpression of the HER2 gene or gene amplification in gastric and breast cancers predicts response to anti-Her2 drugs like trastuzumab. Chemotherapy sensitivity and resistance assays, which have been researched in a variety of tumor types, are potential somatic biomarkers for predicting response to therapy. These assays are offered commercially and have been the subject of numerous published clinical investigations (25).

Biomarkers can be utilized to identify early disease recurrence in patients who have finished adjuvant therapy before they experience symptoms. For instance, serial monitoring of CEA after adjuvant treatment for colon cancer is done to look for liver metastases while they are still treatable and resectable (26). Similar to this, beta HCG, lactate dehydrogenase, and alpha-fetoprotein are serially examined in non-seminomatous germ cell tumors to look for early disease recurrence. Additionally, biomarkers can be used to monitor the efficacy of treatment in the context of metastatic disease. Circulating soluble protein tumor indicators such CEA, PSA, CA125, the MUC1 antigens CA15, CA27.29, and CA19, as well as the efficiency of palliative care in metastatic colorectal, prostate, ovarian, breast, and pancreatic cancers, are suggested (27).

2.1. Synthetic biomarkers

Some researchers are adopting a different strategy rather than depending on endogenous signals, which come from the body. They are tricking a tumor into secreting synthetic biomarkers that can be detected in biofluids while the tumor is still undetectable by any existing technique by using cunning engineering technologies and tumor-specific biological knowledge. When ingested, the exogenously supplied bioengineered sensors can send out a signal indicating the presence of cancer cells. These techniques have successfully detected significantly lower tumor sizes in animal models (28). The biological, physiological, and statistical constraints of endogenous biomarkers serve as a justification for the development of synthetic biomarkers. Endogenous biomarkers such as proteins in the pool of blood and having varying secretion rates are difficult to detect due to short periods of retention and frequent clearance from circulation (29). These represent a new class of diagnostics that use bioengineered sensors such as molecular probes or genetically encoded vectors that take the advantage of the potentially dysregulated characteristics of early stage tumors or their precursors which could become lethal, inside the body to scan for early stage tumors and amplify illness signals to levels that may be greater than those of shed biomarkers detectable from body fluids such as blood and urine. Several imaging techniques also employ synthetic biomarker approach including reporter gene imaging, in which an exogenous molecular tracer (such as a positron emitting probe) is systematically infused (29). Synthetic biomarkers on the basis of their activities are called protease-activated synthetic biomarkers that are particularly effective molecular amplifiers. Apart from it vector-based, mammalian cell-based, and bacterial cell-based synthetic biomarkers are also employed on the basis of their advantages (Figure 1). Moreover, some preclinical studies have reported the potential use of activity-based sensor composed IONPs synthetic biomarkers for early detection of LS174T colorectal cancer (30).

FIGURE 1

Figure 1. A detailed diagrammatic overview of Synthetic Biomarkers on the basis of their activity and various methodologies for endogenous administration.

3. Biomarkers for early detection of colorectal cancer

Colorectal cancer is treatable if caught early enough. As a result, early identification of colorectal cancer can minimize mortality. The categories of colorectal biomarkers that are now studied include proteins, mutated and methylated DNA, RNAs that are mostly microRNAs, volatile organic chemicals, alterations, and variations in gut microbiota makeup. It is generally known that early-onset CRC is becoming more common and is more deadly among those under the age of 50. These patterns have prompted thorough research aimed at clarifying the epidemiology and characteristics of early-onset CRC as well as formulating tactics for early identification and prevention. It is generally known that during the past 30 years, early-onset CRC incidence has grown globally (31). The identification of blood-based biomarkers may be a useful screening method for CRC due to how simple it is to donate or collect blood. A significant percentage of sporadic, non-hereditary malignancies have genetic abnormalities in the initial phases of carcinogenesis. Large numbers of these aberrant cells are shed from the expanding tumor, and their cell-free nucleic acids can be found in biological effluents, especially in urine, serum, and faeces. To promptly detect genetic disorders, molecular biomarkers with higher sensitivity and specificity than the faecal occult blood test (FOBT) or faecal immunochemical test (FIT) can be utilized (32). The biomarkers can be grouped into broader categories: Blood, Tissue, Stool, and Others.

3.1. Blood biomarkers

1. Tumor cells in circulation: According to a recent study, a limited fraction of circulating tumor cells (CTCs) with the ability to cause metastasis include those that express the molecules; EpCAM, CD44, CD47, and MET. It has been found that individual CTCs from the same patient have different KRAS, BRAF, and PIK3CA mutations. CTC are detected using flow cytometry and immunocytochemical analysis are also highly sensitive methods to detect biomarkers for CRC (33).

2. Tumor DNA in circulation: There is circulating tumor DNA or ctDNA called cell-free DNA (cfDNA) in cancer patients that are a diagnostic biomarker for CRC (34). cfDNA contains mutations, methylation, microsatellite instability, and loss of heterozygosity that contribute to tumor-specific alterations (35). There is a high concentration of cfDNA in neoplastic disease. The ctDNA/cfDNA is considered a novel biomarker for the early detection of colorectal malignancies.

3. Micro RNAs in circulation: Non-coding RNAs subclass contains more than 38,500 microRNAs in human beings discovered so far. Circulating upregulated or downregulated miRNAs like miR-18a, miR-31, miR-145, miRNA-486, miRNA-320, miRNA-451, etc., are sensitive biomarkers for CRC (36). Other Biomarkers like ctDNA, mSEPT9 DNA, miR-31, miR-141, miR-224-3p, miR-576-5p, miR-4669, miR-21, exosomal miR-548c-5p, lncRNA CRNDE-h, etc. were identified as biomarkers of CRC. Dysregulation of miRNAs is frequent in CRC and hence are potential biomarkers. RT-qPCR and next-generation sequencing (NGS) are a few methods to detect these miRNAs.

4. DNA methylation-based biomarkers: In CRC the most frequent process to occur as compared to genetic mutation is the methylation of the CpG island of the promoter. More than 600 hypermethylated genes have been identified so far. Among these, the best-known biomarker for CRC is the SEPT9 methylated DNA. There are 13 genes in the SEPT gene family, which is located on chromosome 17q25 in the human genome (37).

5. Long non-coding RNA-based biomarkers: Long noncoding RNAs (lncRNAs) have been shown to be stable in blood and to have diagnostic potential during the past 10 years (38). Through processes, such as chromatin remodeling, chromatin interaction, competing endogenous RNAs, and natural antisense transcripts, they can affect cancer cells (39). Because lncRNAs may pass across cell membranes, they can be discovered in a variety of bodily fluids, including blood, plasma/serum, and urine. Various biomarkers used for CRC detection based on these lncRNAs are CCAT1, HOTAIR, LOC285194, RP11-462C24.1, BCAR4, BLACAT1, UCA1, 91H, PVT-1, MEG3, ATB, CCAT1, NEAT1, etc.

6. Others: Pyruvate kinase M2 (PKM2), an isoform of pyruvate kinase enzyme is reported as overexpressed in CRC. PKM2’s great sensitivity makes it appear like a viable blood and fecal biomarker for CRC screening (40).

3.2. Tissue biomarkers

1. Transcription factors: The caudal type homeobox transcription factor (CDX2) is one of many transcription factors that contribute to the development and differentiation of the intestine (41). It is a widely used immunomarker for CRC as it is a tumor suppressor gene in CRC and its expression is lacking in CRC cases. Another transcription factor special AT-rich sequence-binding protein 2 (SATB2) regulates skeletogenesis and is a CRC biomarker with a positivity rate of 83.7% of stage III/IV colorectal adenocarcinomas, 91.4% of stage II and 92.4% of stage I of this malignancy (42).

2. Transmembrane glycoproteins: The A33 antigen, a type I transmembrane glycoprotein of the immunoglobulin superfamily, is expressed in the basolateral membranes of both proliferating cells in the lower regions of the crypts and differentiating cells in the upper regions of the crypts, as well as in 95% of colon tumors in the colon and small intestine (10). Another glycoprotein, a member of the cadherin superfamily, cadherin-17 (CDH17) is a calcium-dependent transmembrane glycoprotein (43). In normal, metaplastic, and neoplastic tissues of the gastrointestinal tract, CDX2 binds to elements in the 50 flanking regions of the gene to regulate this cadherin’s transcription. With a specificity of 50–83.8% and a sensitivity of 96–100%, CDH17 is a helpful immunohistochemical marker for the identification of primary and metastatic colorectal adenocarcinomas (44).

3. Telomerase: Telomeres, which guard the ends of chromosomes, have certain hexameric repeats (TTAGGG)n in them. They control the longevity of cells and chromosomal integrity. A telomere-specific reverse transcriptase (hTERT) found in telomerase is similar in structure and function to viral transcriptase. The replicative capacity of CRCs and the risk of recurrence are increased by the overexpression of hTERT (45). hTERT appears to be a recurrent biomarker that may be utilized to track systemic treatment responses.

4. Cytokeratins: The intermediate filament-forming protein known as cytokeratins is found in the cytoplasmic cytoskeleton. The only cells that exhibit them are epithelial cells. Numerous cellular processes, including cell size determination, apical-basal polarization, protein translation regulation, organelle location, and membrane protein targeting, are regulated by cytokeratins (46). In CRC diagnoses, cytokeratins are frequently utilized as immunohistochemistry markers. Various cytokeratins involved in the prognosis expressed in CRC patients are cytokeratin 7, cytokeratin 20, cytokeratin 20+/cytokeratin 7-, cytokeratin 15, and cytokeratin 18 (47).

3.3. Stool biomarkers

As the exfoliating tumor cells first occur in the large intestine or rectal lumen during colorectal carcinogenesis, stool specimens are more suitable for the early identification of CRC than blood samples (48). The presence of stool biomarkers has resulted in the early detection of CRC. The guaiac-based fecal occult blood testing (gFOBT) and fecal immunochemical test are mostly used for the screening of rectal blood loss, which is the biomarkers in the stool. The fecal microRNA-106a test is used to detect mRNAs in stool (37). Tumor suppressor genes are rendered inactive by hypermethylation at every stage of carcinogenesis, from polyps to colorectal adenocarcinomas. Many genes, particularly those in the promoter region, are methylated in CRC, including APC, MLH1, MGMT, SFRP1, SFRP2, CDK2A, TIMP3, VIM, SEPT, CDH1, and HLTF (49). There are numerous methylated DNA stool biomarkers used in CRC like SFRP methylation, CDKN2A, MGMT methylation, Vimentin methylation, NDRG4 methylation, BMP3 methylation, K-ras mutation, hypermethylated SCNA, etc.

4. Techniques and current advancements in biomarkers for early detection of CRC

4.1. Techniques for early detection of CRC

Early detection and screening for CRC is necessary and could potentially be lifesaving in many cases, as the symptoms of CRC often tend to develop late in the natural course of the disease (50). Multiple methods can be used to screen and perform early diagnosis of CRC, each with its associated advantages and disadvantages. The most important feature of these tests is the test’s sensitivity, and to a certain degree, its specificity (51).

4.1.1. Colonoscopy

Endoscopic procedures involve passing a camera attached to a long flexible tube into the gut of the patient. These procedures can be used to visualize and non-surgically remove adenomas and early cancers (52). Currently, colonoscopy is the most prevalent method for diagnosing CRC or confirming the positive result from other screening methods, with most doctors suggesting regular colonoscopy at a gap of 10 years for patients over the age of 45. A colonoscopy can be performed to spot and remove pre-cancerous lesions and tumors across the entire large bowel (53). Its sensitivity for CRC detection is around 95%, and for advanced adenomas (about 10 mm in diameter) its sensitivity is around 88–98%. It has been seen in case–control studies that with the use of colonoscopy there was a decline of about 53–72% in the incidence of CRC and a 31% decline in CRC-associated mortalities (54). But colonoscopy has its associated disadvantages, like high dependency on the operator, significant burden to the patient, expensive nature, post-colonoscopy CRC risk, etc. (55).

4.1.2. Sigmoidoscopy

Flexible sigmoidoscopy (FSIG) enables the endoscopic examination of the rectum and, distal colon (56). FSIG is most performed without sedation, unlike colonoscopy (57). Concerning colonoscopy, has its advantages it requires less intestinal preparation, takes less time, causes less discomfort for the patient without anesthesia, has fewer complication rates, and is cheaper (58). The common risk associated includes bleeding and perforations (59). Within this test’s reach, the sensitivity and specificity for large adenomas and CRC have been found to be 95 and 87%, respectively.

4.1.3. Colon capsule endoscopy

Colon capsule endoscopy or CCE is a recent development in the field of CRC screening and involves swallowing a wireless camera, which has the size of a pill, which moves along the GI tract taking images of its surroundings (60). For advanced neoplasia, 10 mm or larger, the CCE-2 has a sensitivity of 76.7% and a specificity of 90.7% (61). g-FOBT and fecal immunochemical tests Guaiac Faecal Occult Blood Tests or g-FOBT involve the testing of stool for the presence of blood in it. The stool sample is tested using peroxidase enzyme for the presence of the heme group using a guaiac card. A positive g-FOBT necessitates a follow-up colonoscopy test (12). Fecal Immunochemical Tests or FITs incorporate antibodies that specifically bind to the globin protein of hemoglobin. Thus, like g-FOBT, they also search for the presence of blood in the stool of the patient (62). The biggest advantage of such stool-based tests is the ease of use. An issue with these techniques is that most polyps do not bleed. Thus, their presence goes undetected with these tests.

4.1.4. Stool DNA testing

This non-invasive method tests for the presence of molecular debris and occult blood in the stool samples (63). This debris might include mutant DNA seen in tumor cells, like mutant KRA, p53, aberrantly methylated BMP3, NDRG4 promoters, etc. (64). Cologourd®, an FDC-approved multi-target stool test, has been shown to have higher sensitivity than FIT (92 and 72% respectively) but lower specificity (92 and 74% respectively), in a study that tested both on nearly 10,000 patients, using colonoscopy as reference. It also had a low detection rate for large advanced melanomas of only 42%, therefore limiting its preventive role (64).

4.1.5. Computed tomography colonography

Computed tomography colonography, or CTC, provides images of the entire abdomen and pelvis, not just the colon. It uses a radiographic agent to non-invasively tag stool for digital imaging. CTC’s per-person sensitivity for adenomas below 10 mm varied between 66.7 to 93.5% in a meta-analysis evaluating its effects with colonoscopy, while its specificity values ranged from 96.0 to 97.9% (65).

4.1.6. Double-contrast barium enema

Double-contrast barium enema or DCBE is performed without any use of sedative and involves the injecting of air and rectal contrast and is therefore an unpleasant experience for the patient. But it can evaluate the entire colon for any abnormality (51). A study between DCBE and colonoscopy showed that DCBE detected only 32% of polyps less than 5 mm, 53% of polyps 6 to 10 mm, and only 48% of those greater than 1 cm (66).

4.1.7. Serological tests

A blood-based detection test, or liquid biopsies, checks for DNA markers floating in blood. The presence of methylated septin 9 in plasma has been assessed in many studies (67). According to a meta-analysis study that was based on 25 research articles, the SEPT9 assay is only better than the FIT in the symptomatic group (68). The test’s current commercially available iteration has a sensitivity for advanced neoplasia and CRC of 25 and 68%, respectively, with a specificity of 79% (69, 70) (Table 2).

TABLE 2

Table 2. Summary of detection techniques used for CRC detection based on cost-effectiveness.

4.2. Current advancements in biomarkers for early detection of colorectal cancer

The need for more specific and sensitive biomarkers to detect CRC arises from the fact that CRC is one of the top four most prevalent cancers worldwide (71) with a high mortality rate. The current non-invasive techniques used for screening, for example, are not very sensitive to the earlier stages of cancer and may miss any pre-cancerous lesions and polyps. According to Imperiale et al. (72) “In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results” (73). The finding further establishes the need for more sensitive biomarkers along with the already used screening techniques. The emergence of gene expression analysis along with transcriptome studies has allowed scientists to categorize CRC into subtypes for developing a better understanding of the disease and for devising better treatment strategies based on the subtype of CRC a patient may have. (74)Maida et al. (Maida et al., 2017) performed Molecular sub-typing of colorectal cancer, dividing it into 4 major subtypes: CMS1, CMS2, CMS3, and CMS4. This analysis has also elucidated new biomarkers. Similarly, Multi-Omics studies analyzing large amounts of data on the structure and function of several biological molecules in their totality have led to a better understanding of multifaceted and complex diseases like cancer. The omics studies including genomics, transcriptomics, proteomics, metabolomics, glycomics, etc. have revealed many new promising biomarkers for CRC. These biomarkers include several different kinds of molecules which may be DNA–RNA-based, protein-based, metabolite-based, or even volatile substances found in a patient’s breath. They can be detected utilizing techniques like genomic analysis, mutation analysis using hybridization arrays, micro-arrays, bioinformatics analysis, mass spectroscopy, Gas- Chromatography MS, Gel electrophoresis, etc. (9).

5. Effect of NSAIDS on the gastrointestinal system

PGs increase mucus production and PGI2 and PGE2 have a vasodilator effect on the vasculature of the gastric mucosa and reduce gastric acid output. On the other side, NSAIDs could prevent the effects of PG on the gastrointestinal tract. Mucosal proliferation, HCO₃ secretion, and mucin synthesis are all inhibited by this action. NSAIDs can damage the gastrointestinal tract by impairing this function, which can lead to stomach problems (75). Gastric hypermotility results from NSAID usage that inhibits COX-1. Although the exact process is unknown, it is possible that tissue hypoxia and microvascular damage arise from high-amplitude, limited blood flow. There is some evidence that NSAID usage may lower the chances of GI malignancies, including gastric, pancreatic, and colorectal cancers, in contrast to the acute effects of NSAIDs on the GI tract (76). For instance, multiple studies have discovered that NSAIDs without aspirin are linked to a lower risk of gastric cancer (77) and, in the case of celecoxib, a higher rate of per-cancerous gastric lesions regressing when compared to placebo. To identify these possibly beneficial effects more fully, more research is nonetheless required (78).

5.1. Effect of NSAIDS and relation between cancer and inflammation

Acute inflammation, also known as resolved inflammation, is a self-limiting adaptive host defense mechanism that brings the body back to a state of homeostasis. However, persistent, unchecked, or unresolved inflammation can result in a number of diseases, including cancer. Nonsteroidal anti-inflammatory drugs (NSAIDs), like aspirin, lower the risk and death from several malignancies, which is significant evidence that connects inflammation and cancer. Clinical studies using COX-2 inhibitors for cancer prevention or therapy were justified by the overexpression of COX-2 in the colon and many other malignancies. NSAIDs, on the other hand, do not need COX-2 to prevent cancer (79).

Since ancient times, it has been understood that the primary reaction to damage is “Inflammation.” Hippocrates, a Greek physician, may have been the first to view inflammation as the start of a healing process and used terms like erysipelas and edema to characterize its symptoms (80). The body’s reaction to an exposure, such as an infection or an injury, is inflammation. NSAIDs have been identified as the prototype chemopreventive drugs against several types of cancer by more than 30 epidemiological investigations that combined reported findings on more than one million participants. NSAIDs can affect the microenvironment of tumors by slowing cell migration, boosting apoptosis, and decreasing chemosensitivity. Targeting the molecules (COX-2 cyclooxygenase 2, NF-kB, VEGF) involved in the inflammatory process might offer a useful technique for cancer prevention and therapy since they can predispose to tumors (81). Several NSAIDs like aspirin, celecoxib, piroxicam have shown preventive effects on inflammation in colorectal cancer. Colorectal cancer-related prevention by NSAIDs mostly works by acting on the pathway of the eicosanoids (82). NSAIDs have been shown in the past to have anti-tumor effectiveness, less toxicity, and non-specific side effects than those caused by conventional chemotherapy. They were also able to limit tumor growth by causing changes in the inflammatory environment of the tumor (83). NSAIDs have demonstrated chemoprotective and anti-inflammatory effects on inflammations associated with tumors. The fact that COXIB has more notable protective advantages than non-selective NSAIDs against a variety of malignancies is associated with a larger reduction in the risk of cancer (84, 85).

6. Role of NSAIDs in colorectal cancer chemoprevention

Cyclooxygenase (COX)-dependent and independent pathways participate in anti-tumorigenesis, albeit their mechanisms are not completely known (86). The primary anticancer action of NSAIDs is assumed to be a COX-2 inhibition-mediated suppression of prostaglandin E2 production, which reduces tumor cell proliferation, angiogenesis, and enhances apoptosis. Various signal transduction pathways like nuclear factor-kappa B, NF-κB, have been proven as COX-independent NSAID-induced effects, despite the fact that many of the anticancer mechanisms of NSAIDs are described as COX-dependent. Numerous studies have been conducted on the relationship between expression of COX and colorectal cancer, including prognostic variables and potential chemo-preventive drugs (87).

6.1. Mechanism of anti-cancer activity of NSAIDs

6.1.1. COX dependent pathway

COXs are regulators that have critical roles in carcinogenesis, angiogenesis, and inflammation. COXs found on luminal side of the ER (endoplasmic reticulum) are connected with the nuclear envelope and have three isoforms: COX 1, COX 2, and COX 3 (58, 88). The pharmacological basis for anti-inflammatory activity of NSAIDs is believed to be the inhibition of COX 1 and COX 2 enzymes, which catalyse conversion of arachidonic acid into prostaglandin H2, a precursor for the formation of prostacyclins, thromboxanes and prostaglandins. These eicosanoids have been associated to pain, fever, and inflammation. Moreover, they protect stomach and gut lining from harmful impact of the acid, stimulate blood clotting by activating blood platelets, and control kidney function. COX 2 is triggered by inflammatory stimuli, whereas on the other hand COX 1 is constitutively expressed in several tissues and has a significant role in the tissue homeostasis (89).

Several molecules linked to inflammatory and malignant processes have their gene transcription and protein synthesis regulated by aspirin and NSAIDs (90). The ability of NSAIDs and aspirin to decrease COX expression and downstream signals, that are essential for CRC cell diffusion, survival proliferation, allows for differentiation of these actions. Arachidonic acid is transformed into prostaglandin G2 by cox enzymes which is an unstable intermediate that is quickly degraded into PGH2. After that, PGH2 is transformed in a number of PGs with comparable structural properties, such as Thromboxane (TX) A2, PGD2, PGF2, PGI2, and PGE2 (91). Despite the fact that research in experimental CRC models has shown that COX 1 may promote cancer growth, in mammalian tissues, COX 1 is expressed constitutively, and PGs synthesized from COX 1 are required for physiological functions (56).

On the other hand, COX 2 is activated in various cell types by tumor promoters, growth factors, and inflammatory cytokines (92). In 80-90% of carcinomas and 40–50% of human colorectal adenoma cancers, COX-2 expression is elevated, which increases PG synthesis (93, 94). Platelet-derived growth factor, matrix metalloproteinases, and vascular endothelial growth factor are all vital for the genesis, development, and advancement of tumors. COX 2 stimulates the synthesis of these molecules. Additionally, COX-2 restricts the development of immune cells with antineoplastic activity and controls the production of proteins that are both pro- and anti-apoptotic (61, 95).

Aspirin is the NSAID which has the ability to permanently suppress COX 1 and COX 2 action. On antiplatelet therapeutic levels of 75-100 mg daily, aspirin is 100-fold more effective than monocyte COX-2 in suppressing platelet COX-1 (96). Platelet activation in CRC patient stimulates the generation of proteolytic enzymes and chemokines which promote metastasis, angiogenesis and cancer cell proliferation (97). Activated platelets may potentially contribute to COX 2 overexpression in CRC by producing TGF, IL-1 and platelet-derived growth factor (97). Aspirin’s anti-platelet activity may thus be responsible for some of its anti-tumorigenic actions. Aspirin and other NSAID suppression of PGE2 and COX 2 synthesis may depend on modulating a variety of signals which also includes sphingosine-1-phosphate (S1-P) synthesis suppression and activation of NAG-1, a gene induced by NSAID.

6.1.2. COX independent pathway

COX inhibition does not account for all of the NSAID-mediated anticancer effects. In fact, not all NSAIDs which are COX inhibiting possess anticancer effects and reactivating COX does not release the CRC cells from the arrested cell growth induced by NSAIDs. Additionally, CRC cells deficient in COX experience NSAID-induced apoptosis and growth inhibition (98).

6.1.2.1. NF-κB activation

Different subunits of the NF-κB family are regulated by NSAIDs in Colorectal cancer and can combine to produce homodimers and heterodimers. Among these, the binding of the RelA (p65) and p50 heterodimer occurs in an inactive state in cytoplasm with the help of I-kappaB (IκB) inhibitor protein. The translocation of this heterodimer to nucleus occurs in response to the activating stimuli which leads to phosphorylation of IκB with its subsequent degradation by proteasome. Translocated p50/RelA heterodimer controls the transcription of various genes (99). Reduced NF-κB transcriptional activity is resulted from the nucleolar sequestration of RelA induced by a dose of 5–10 mM of aspirin in cultured CRC cells (100). A dose of 50 μM of Sulindac sulfide limits the HCT-116 invasion of cells by inhibiting transcription (mediated by NF-κB) of some particular microRNAs like miR 9, miR 17, miR 21 which regulates gene expression implicated in metastasis and tumor cell invasion (101).

6.1.2.2. Wnt/β-catenin pathway

Wnt/β-catenin pathway (Wingless and integration site growth factor (Wnt)/-catenin) is a pathway that NSAIDs can target easily, since it is active in most of the CRC cells. A protein called cytoplasmic disheveled (Dsh) protein is activated by binding of Wnt with TFR (transmembrane frizzled receptor). The glycogen synthase kinase 3 (GSK3), casein kinase 1 (CK1), protein phosphatase 2A (PP2A), axin, and Apc, make up the catenin destruction complex, which Dsh protein binds with. The ubiquitination and degradation of the destruction complex is facilitated by the phosphorylation of the cytoplasmic β-catenin while Wnt signaling being absent (102). However, a decrease in the β-catenin degredation in response to the Wnt signals is seen with the aggregation of cytoplasmic β-catenin and gradual translocation to nucleus. Therefore, gene expression that promote tumor, for example, c-jun, peroxisome proliferator-activated receptor delta, c-myc, cyclin D1, and matrilysin is stimulated by the binding of β-catenin with the family components of LEF (lymphoid enhancer factor) and TCF (T-cell factor) (103).The β-catenin phosphorylation is enhanced by 5 mM and 100 mM doses of aspirin and celecoxib which reduces its nuclear aggregation and, as a result, transcription of Wnt/-catenin target genes in colorectal cancer cells (104). A study reported more data supporting the Wnt/-catenin pathway as a target of NSAIDs in CRC chemoprevention. According to this study, a 50 μM dosage of sulindac sulphide suppresses TCF transcriptional action of Wnt/β-catenin without enhancing phosphorylation of β-catenin, hence downregulating cyclin D1, and specifically inhibiting CRC cell proliferation (105). Several types of NSAIDs and their chemical structures have been discussed under Table 3 (Figures 2, 3).

TABLE 3

Table 3. A systematic representation of mechanism of action of NSAIDs along with their advantages and drawbacks.

FIGURE 2

Figure 2. Cox-dependent and independent mechanism overview associated with NSAIDs. Cyclooxygenase dependent and independent pathways play a significant role in anti-tumorigenesis. The major anticancer action of NSAIDs is thought to be COX 2 suppression mediated decrease of prostaglandin E2 synthesis, which inhibits tumor cell proliferation and angiogenesis while increasing apoptosis.

FIGURE 3

Figure 3. An overview of downstream targets in colorectal cancer & NF-κB and β-catenin/Wnt pathways. Catenin accumulates as a result of APC gene or activating mutations in the β-catenin, which leads to the formation of complex with the TCF/LEF transcription factors. TCF can interact with extra to stimulate the transcription of genes which are proliferative in the colon, including c-Myc and cyclinD1. With the release of p65, that is subsequently translocated to nucleus, inflammatory cytokines activate NF- κB, which leads to an increase in target gene transcription. NSAIDs in combination with other drugs like naproxen or sulindac targets β-catenin /Wnt and NF-κB pathways and suppresses downstream signaling.

6.2. Combined use of statins and NSAIDS for synergistic effect in CRC-chemoprevention

The drugs which lower cholesterol, also known as statins are made of tiny molecules called 3-hydroxy-3-methyl glutaryl coenzyme-A (HMG-coA) reductase inhibitors. Since statins show anti-carcinogenic characteristics in several in vitro and in vivo preclinical tests, there is a great interest in finding out how they might be used in cancer chemoprevention. Statin use may offer some preventive benefits against total cancer risk, according to some observational human research, but not others (113).

Statins are routinely used to reduce cholesterol and NSAIDs are mainly used to treat inflammation. Recent studies have focused on their potential function as cancer chemo-preventive drugs. Human studies have not shown solid data on the protective benefits of statins against various malignancies, although NSAIDs have yielded more compelling results for cancer prevention, particularly in CRC. Combining statins with NSAIDs may induce synergy and result in a reduction in the doses needed for each agent, which is a potential technique for improving cancer prevention effectiveness. This method is of particular importance for the prospective long-term utilization of low dosages of NSAIDs and statins for cancer chemoprevention. Significantly, colorectal cancer chemo-preventive studies have shown elevated possibility for gastrointestinal and cardiovascular adverse effects linked to NSAID usage. A growing body of research has conclusively shown that NSAIDs help prevent cancer, particularly colorectal cancer. Because of the potential elevated risk of severe cardiovascular and gastrointestinal side effects, relatively high dose needed to produce the observed chemo-preventive benefit in human studies can dissuade the long-term usage of NSAIDs alone for cancer prevention (114). Emerging research suggests that combining cancer chemo-preventive drugs, NSAIDs with distinct mechanisms of action may result in synergistic interactions, which might result in far higher anti-carcinogenesis benefits than each chemo-preventive agent could independently. NSAIDs have demonstrated synergistic effect in various other in vitro studies when treated with other therapeutic agents for example EGFR family inhibitors, statins, TRAIL receptor ligands, and PPARg ligands (115).

The combined use of statins and NSAIDs is particularly intriguing for cancer prevention. Atorvastatin is an example of the drug that was prescribed most in the year 2006 in US. In a significant experiment, to examine the results in individuals with coronary artery disease, pravastatin usage was found to be linked to a 43% decrease in several newly detected instances of colon cancer. Notably, 83% of individuals in both placebo and pravastatin groups received aspirin every day, implying that interaction between aspirin and pravastatin may have an improved protective impact (116).

The effects of statins and aspirin on risk of CRC were studied in a population-based case control research (117). This study comprised 612 controls and 537 patients with CRC cases that had been histologically proven. Frequent use of aspirin at a low dosage level was linked to a moderate reduced risk for CRC, whereas frequent use of statins, primarily simvastatin and atorvastatin, was linked to a stronger risk reduction. The most intriguing finding was that taking statins and lower dose of aspirin together for 5 years or more was linked to 62% risk of risk in CRC.

Utilizing the AOM rat model, effectiveness of celecoxib, aspirin, and atorvastatin against colon carcinogenesis when given separately on high dosage levels and when combined at low dosage levels (118). In comparison to single high doses of atorvastatin given at 150 ppm or celecoxib given at 600 ppm, the combination of 100 ppm atorvastatin and 300 ppm celecoxib reduced the prevalence and multiplicity of adenocarcinomas. Accordingly, low-dose combination of atorvastatin and aspirin significantly inhibited the prevalance and multiplicity of adenocarcinoma when compared to higher doses of each treatment alone. The effects of celecoxib and atorvastatin was examined on growth of adenomatous polyps in intestines in a different experiment utilizing the ApcMin/+ mouse model. Combining atorvastatin and celecoxib at 100 ppm and 300 ppm, respectively, was found to completely suppress colonic adenomatous polyps and reduce adenomatous polyps in small intestines by 86%. However, these effects were more potent than those brought on by either celecoxib or atorvastatin treatment administered separately (119). Together, these findings certainly showed that statin/NSAID combination regimens significantly increased the effectiveness of either type of agent administered alone in preventing cancer. This strongly supports the use of the statin/NSAID combination as a promising method for cancer chemoprevention.

6.2.1. Pathway involved

The pathways through which statins and nonsteroidal anti-inflammatory drugs (NSAIDs) limit cancer cell proliferation, induce apoptosis, and block other procarcinogenic processes are not completely known. Examples of celecoxib and atorvastatin were selected to briefly describe the potential mechanism of statins and NSAIDS as cancer chemo-preventive medications. By inhibiting HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway, statins reduce the formation of isoprenoids such geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP; FPP). These isoprenoids are necessary for the isoprenylation, membrane localization, and subsequent activation of a number of signaling proteins, such as Ras, Rho, and Rac. In contrast to GGPP, which can stop the apoptosis that statins cause in cancer cells, add-back assays showed that FPP had little to no protective benefits (120). These results demonstrated that GGPP had a more significant contribution to statin-induced effects than FPP. Studies have shown that geranylgeranylated Rho proteins play a part in the effects that statins induce, whereas the findings on farnesylated Ras have been contentious (121).

The specific mechanism by which statins and NSAIDs operate synergistically to create improved anti-carcinogenic effects remains largely unknown. A study was carried out on colon cancer HCT 29 and HCT116 cells. The mode of action was studied, and a strong synergistic effect was observed (122). Cell cycle arrest in the G0/G1 phase was brought on by the atorvastatin/celecoxib combination therapy for 24 h, and this effect was substantially stronger than those brought on by atorvastatin or celecoxib alone. These results are in line with those from animal studies, which showed that atorvastatin and celecoxib combination therapies reduced proliferative index and elevated apoptotic index in tumor tissues. Other studies in cancer cells demonstrated increased apoptosis with statin and NSAID co-treatments (123).

According to research, atorvastatin lowers the level of membrane bound RhoA, probably by isoprenylation inhibition and its impact is greatly boosted when combined with celecoxib (124). This may inhibit RhoA’s carcinogenic actions, which have been linked to cell cycle progression, enhanced tumor invasiveness, and metastasis (125). The suppression of RhoA’s membrane attachment is one potential method by which the combination of atorvastatin and celecoxib might cause cell cycle arrest. This can cause disruption of RhoA’s negative control on both p21Cip1/Waf1 and p27Kip1 and that may raise the levels of these two CDK inhibitors (126). Unlike RhoA, the combination of atorvastatin and celecoxib raised the membrane-bound RhoB by an unknown mechanism. Due to the potential tumor-suppressing action of RhoB, the enhanced membrane association of RhoB may contribute to the inhibitory effects of atorvastatin/celecoxib combo on cancer cell proliferation (127). Celecoxib was discovered to strongly synergize with atorvastatin to abolish phosphorylation of Akt in colon cancer cells, even at low doses when little or no inhibition on Akt was shown on its own (128). The same treatments decreased Akt’s upstream kinases, PDK1 and PI3K, phosphorylation levels. Furthermore, by reducing PTEN’s phosphorylation at Ser380, the combination therapy may have elevated PTEN activity. In colon cancer cells treated with celecoxib or atorvastatin alone, all of these effects were either completely absent or markedly diminished. The apoptosis brought on by the combination of atorvastatin and celecoxib therapy may be significantly influenced by the suppression of the Akt pathway (128). It is crucial to note that neither of the two human colon cancer cell lines used had enough COX-2 expression. HCT11 cells lack the enzymatically inactive COX-2 protein that HT29 cells express (129). As a result, the effects of celecoxib and its combination with atorvastatin reported in this study were COX-2 activity independent. Findings on the combined treatment of licofelone (a dual inhibitor of COX-1 and 2) as well as 5-lipoxygenase, and atorvastatin did not show a significant synergy in inhibiting HCT116 cellular proliferation. More research is required to validate the involvement of COX-2 in the statin/NSAID combined treatment (Figures 4, 5).

FIGURE 4

Figure 4. Anticancer effects exerted by Statins by inhibiting mevalonate pathway. Acetyl-CoA, the byproduct of glycolysis, is converted into mevalonate, IPP, GPP, FPP, GGPP, and cholesterol through a series of enzymatic processes that make up the mevalonate pathway. FPP and GGPP may both be supplemented to proteins post-translationally, particularly minor monomeric GTPases such as Ras predominantly part of MAPK/ERK pathway responsible for inducing VEGF expression in colorectal cancer. The inhibitory effect of FPP on MAPK/ERK pathway and inhibition of mevalonate pathway by statins causes tumor cell death and prevents migration of tumor cells. Statins shows its inhibitory effect on VEGFR and EGFR thus, inhibiting angiogenesis and tumor progression in cancer. It also inhibits BCL2 and induces aoptosis of cancerous cells.

FIGURE 5

Figure 5. Synergistic action of statins and NSAIDs: Statins repress and activate signaling cascades that result in cell-cycle arrest, cell death, apoptosis, and autophagy when used with anti-cancer medications such TRAIL, troglitazone, celecoxib, gemcitabine, cisplatin.

6.2.2. The Nanoformulation of NSAIDs for CRC chemoprevention

Nanotechnology encompasses a wide range of novel and extraordinary nanomaterials with diagnostic and therapeutic potential. Carbon nanotubes, liposomes, dendrimers, gold nanoparticles, silica nanoparticles, and other nanomaterials are employed in colorectal cancer diagnosis and therapeutic delivery. Various drugs loaded on gold and silica nanoparticles are engaged in the death of CRC cells by targeted delivery of anticancer medications to cancer cells. With technological innovation, new approaches incorporating the utilization of nanotechnology have paved the way for the manufacture of nanomaterials capable of treating CRC cancer as well as other tumor types. These approaches have also aided in the identification and screening of CRC. The use of nanotechnology in CRC is crucial for the development of tailored drug delivery systems, the early detection of malignant tumors (which are nanomaterial-based), and several other improved therapeutic approaches. Regarding the present progress of nanotechnologies in the treatment of CRC, it has gained global attention due to its capacity to enhance screening techniques as well as diagnosis and therapy. Nanoparticles have been shown to increase current information on biochemical and physiological principles underlying a few diseases and their therapies. Nanoparticles have shown improved performance in few techniques like PET (positron emission tomography) and MRI (magnetic resonance imaging) with the respective use of radioisotope chelator-free nanoparticles in PET and iron-oxide based nanoparticles in MRI.

Due to their small size, remarkable sensitivity, and unique chemical constitution, nanoparticles are ideal contrast agents and are frequently employed in the treatment of cancer. When used therapeutically, it enhances the aggregation and discharge of pharmacologically active substances at the diseased site, increasing therapeutic efficacy and minimizing adverse toxic side effects. Additionally, NPs which have been recently developed have the capacity to combine diagnostic and therapeutic compounds into a single nanoparticle that is simple to employ for theranostic applications. Theranostic nanoparticles (NPs) may also be used in individualized nanomedicine-based therapeutics, according to studies. To develop an efficient treatment for colorectal cancer, new technologies for detecting proteins, genes, and other components in an individual’s cancer should be devised. Anti-angiogenesis therapy is an alternative for CRC treatment in addition to EGFR inhibitor therapy. The most prevalent negative effects of targeted treatment are appearance of upper body and facial rashes. Poor drug responsiveness to chemotherapy while treating CRC is commonly observed, and this may be largely because of the development of multidrug resistance in tumor cells. Nanomedicine is believed to be a current method to improve the prognosis and treatment for CRC patients in order to combat multidrug resistance.

Numerous significant nanotechnological applications in cancer biology have been established, including early cancer screening and diagnosis as well as the development of novel therapy modalities that cannot be achieved with the currently available conventional technologies. In fact, particles bearing nano sizes of various forms and constitution have evolved as crucial and promising innovative tools for colorectal cancer screening, diagnostics, and treatments.

Different nano-formulations have been developed throughout the years to enhance curcumin delivery to cancer cells or tissues. Nano-formulations are generally utilized to improve solubility of curcumin in water and provide more constant curcumin administration (107, 130). Also, Curcumin nano-formulations treating tumors should ideally have increased anticancer efficacy when compared to curcumin alone and be harmless to normal cells.

Various studies have reported the documentation of curcumin nano-formulation for colorectal cancer treatment. The studies involve the use of polymeric nanoparticles, nano gels, liposomes, gold nano particles, cyclodextrins, solid lipid nanoparticles etc. Even though several nano formulations are through clinical testing, the number of nano formulations employed in CRC clinical trials is restricted. With the improvement in the designing of nano devices, nanomedicine has demonstrated its effectiveness in transforming the treatment and diagnosis of cancer. The drug-encapsulation methods that are on the nanoscale are particularly effective in passively retaining additional drug-loaded NPs close to cancer cells. These tactics have aided in the establishment of the subsequent generation of anticancer nanomedicine.

The main purpose of NSAIDs is to prevent colon cancer. The epidemiological studies show that aspirin is the most promising NSAID of all the reported ones. Whereas the prevention of colon cancer by aspirin either alone or in combination has been demonstrated, nano encapsulation of aspirin can increase its effectiveness at a lower dose. A study conducted on seven-week-old male Sprague Dawley rats which were treated with azoxymethane revealed the chemo protective impact of calcium, folic acid, and aspirin. It was discovered that this combination was 1.7-fold more effective than their unmodified complement routine (111, 131). The clinical uses of another NSAID, known as celecoxib in context of chemo preventive activity has been widely explored. The preparation of celecoxib polymeric Nanoparticles with ethyl cellulose, lipid hybrid nanoparticles, sodium casein ate bile salt, and micro emulsions improved the drug’s bioavailability and permitted a reduction in dosage, crystallization, and associated toxicity. Phytochemicals are naturally derived plant-based compounds that are widely explored as possible chemo preventive agents and they are non-toxic and have pleiotropic properties. Curcumin has demonstrated effective chemoprotective effects in colon and intestine cancer, although it exhibits limited absorption, minimal solubility in water, and poor bioavailability. To address the issue, nano capsules of curcumin whey protein were produced, which not only demonstrated >70% discharge after 48 h but also increased bioavailability and cell internalization. In subsequent studies, it was discovered that encapsulating curcumin using polymeric nano carriers improved its solubility and the treatment group receiving curcumin nanoparticles demonstrated fewer structural abnormalities, a significant decrease in tumors, and beta-catenin levels than the group receiving curcumin alone.

In the future, this knowledge might be utilized to generate new approaches for the continued development of nanotechnology to upgrade existing medications and produce newer therapeutics.

6.3. NSAIDs – Dosage and duration and their therapeutic effects

Studies on the detection of colorectal cancer and its prevention are currently an expanding area of clinical oncology because it is one of the most prevalent tumors in the world. An analysis of randomized controlled, double blinded clinical studies including a few NSAIDs such as aspirin, sulindac, and celecoxib and colorectal cancer chemoprevention was done for this study. People taking NSAIDs had a decreased incidence of CRC, which points to the medications sustained chemo-preventive effects in both per-clinical and clinical studies. This advanced method of treating colorectal cancer could make it less fatal and more manageable. Clinical trials have examined and analyzed different NSAIDs for their proper dosage, duration, and therapeutic effects on CRC chemoprevention (110, 132, 133). Evidence from these clinical trials determined the extent of their chemopreventiveness in CRC. Seven trials on the use of aspirin in monotherapy, polytherapy with folic acid or eicosapentanoic acid for the prevention of CRC has been completed to date. For aspirin one such study involved the people with a history of CRC and not the ones with FAP or HNPCC. Patients had to wait for at least 5 years following tumor removal before experiencing a relapse to be eligible for carrying out colorectal adenoma prevention study (CAPS). It was found that the groups receiving aspirin 325 mg per day for 3 years had reduced average number of adenomas recurrence by 35% (134). Similar encouraging results were reached in the Asian population in the clinical trials with ASA 100 mg/day for 2 years, which involved participants with adenoma and a history of colon cancer (135). The Rothwell team also looked at if there was any weight or height dependence and how aspirin affected the risk of colon cancer over the next 20 years. In people weighing 70 kg or more, they found that 75-100 mg of aspirin used once day was ineffective at avoiding cardiovascular events, sudden cardiac death, or cancer, especially in those who smoked or took enteric-coated forms, suggesting that its dosage is too low for treatment (136). Sulindac was the subject of a further double-blind, placebo-controlled investigation in FAP patients. It was discovered that standard sulindac doses did not prevent adenomas from developing in younger patients with FAP (137) despite the fact that the number of scientific experiments with sulindac was significantly lower and was too small to be trusted. They were either given 75 or 150 mg orally twice a day of sulindac or identically looking placebo tablets for 48 months. Contrarily, celecoxib has a proven track record of protecting patients who have previously experienced sporadic colorectal adenomas from developing the condition again. Over 1,500 patients participated in the PreSAP (prevention of sporadic adenomatous polyps) and APC (adenoma prevention with celecoxib) trails. Both studies findings-one evaluating celecoxib at a daily dose of 400 mg for 3 years and the other evaluating daily doses of 400 and 800 mg are in an agreement with each other. Celecoxib’s effectiveness in preventing adenoma recurrence improves with dosage (138, 139). Celecoxib’s effectiveness in treating various tumor types when administered in conjunction with cystostatic medicines or monoclonal antibodies such as gemcitabine, cisplatin, fluorouracil, or cyclophosphamide has been studied. Moreover, in studies involving certain patient population, rofecoxib has shown to have a lower incidence of adenoma recurrence (58). Usually non aspirin NSAIDs use is associated with increased risk of cardiovascular risk and gastrointestinal bleeding which limit their use in CRC chemoprevention (140). However certain case control studies such as the one based on Danish population analyzing non aspirin NSAID use (average daily dose & gt; or = 0.3) was associated with a substantial reduction in CRC risk. Aspirin and non-selective NSAIDs (SIR 0.74 [0.71-0.77]), but not COX-2i, were linked to lower risk of GI malignancies including CRC, according to a Swedish population-based analysis of persons taking frequent NSAIDs (cumulative exposure of 6 months) (141). Another prospective cohort study analysis found that using non-aspirin NSAIDs was linked to a decreased risk of CRC in postmenopausal women (142).

Chemoprevention necessitates the continuous administration of NSAIDs. The case for prescribing a chemopreventive medication is more convincing when the patient’s CRC risk is higher, and the drug’s cumulative side effects are less severe. Traditional NSAIDs have adverse effects that worsen over time, particularly in older patients who take other drugs due to comorbidities that interact with the chemopreventive agent (107, 143). As a result, the CRC risk must be significantly more than the 5% likelihood that a person at average risk will develop CRC in order to sustain the lifetime treatment of a typical NSAID. The use of NSAIDs for cancer chemoprevention is not advised despite the substantial evidence of activity because of the risk of serious renal, gastrointestinal, and cardiovascular adverse effects that arise from COX inhibition and the suppression of physiologically significant prostaglandin (111, 133). The chemopreventive efficacy of NSAIDs is also insufficient, albeit it is unclear whether this deficiency is brought on by dosage restrictions or resistance mechanisms. Hence preventing NSAIDS from getting into more clinical trials and FDA approval in CRC chemoprevention.

7. Advantages, challenges and future perspective of NSAIDs

7.1. Advantages of NSAIDs

Patients who smoked heavily and had a high BMI had decreased ability to benefit from the chemo-preventive effects of NSAIDs, especially aspirin. Ibuprofen use was linked to a lower incidence of CRC in a different cohort study of patients with germline mismatch repair gene mutations (144, 145). The use of both aspirin and non-aspirin NSAIDs was associated with a reduced risk of cancer, including CRC. The FDA has authorized the use of NSAIDs as analgesics, antipyretics, and anti-inflammatory drugs. These qualities allow NSAIDs to be used to treat a wide range of illnesses, such as migraines, pyrexia, gout, arthritic disorders, muscle pain, and dysmenorrhea, and as an opioid alternative in some cases of severe trauma (145). Colorectal cancers with PIK3CA mutations or COX2 overexpression appear to have a stronger correlation between NSAID and aspirin usage and decreased mortality. Thus lending credence to the idea that NSAIDs might be used as adjuvant therapy for CRC. Optimizing the timing of NSAID use as an adjuvant treatment is clinically important. The synergistic anticancer effect of aspirin, biologically, might be explained by the stimulation of apoptosis through a COX-dependent or COX-independent mechanism (107, 146), the decrease of metastatic risk by preventing the contact between platelets and circulating cancer cells (109, 111, 147, 148), or the modification of the antitumor immune response (112, 149). In the end, NSAIDs may have more than one target and most likely has several adjunctive effects.

7.2. Challenges In The Use of NSAIDs As CRC chemopreventive

Despite the immense potential of NSAIDs as chemo-preventive agents, their use in CRC chemoprevention encounters many challenges. The poor acceptability and cost of screening colonoscopies are the two factors that make chemoprevention of colorectal cancer (CRC) a viable approach. The most promising treatment agents are those NSAIDs, which are presently not advised for the prevention of CRC (150). NSAIDs’ limited chemo-preventive effectiveness is exacerbated by their considerable toxicity, which can be cumulative. These limitations can be curbed by the use of drug combinations, and the development of certain classes of NSAIDs that are chemically modified (for example – phospho-NSAIDs, nitro-NSAIDs, sulindac) and thus have prolonged safety than any other type of NSAIDs like those of conventional ones (150). One of the major challenges for using NSAIDs as a chemo-preventive drug is identifying the subjects who will gain the most from the chemo-preventive medication and those who are at potentially higher risk (151). The development of biomarkers that are predictive and techniques to reliably evaluate risk would be immensely beneficial in this case. Another challenge is optimizing chemo-preventive drug delivery time, dosage, and duration. According to research, very brief durations of agent administration may be necessary and can prevent colon carcinogenesis at an extremely early stage (152). The dosage and duration of NSAID administration might therefore be adjusted to ensure that the least amount of NSAID is utilized for the shortest duration of time. Furthermore, for individuals at risk, starting such an intervention at an early age may be beneficial. Also, the use of other new or combined agents or those agents that prevent other diseases in addition to colorectal cancer has its own merits (153). A meta-analysis of aspirin’s role in preventing CRC and other malignancies in recent years published in May 2009 showed frequent aspirin use is linked to a lower risk of cancer. However, this theory raises various issues, such as the best aspirin dose and the prevention of gastrointestinal bleeding brought on by prolonged aspirin usage. Thus, there is still much debate about the use of aspirin in the prevention and treatment of cancer (154).

NSAIDs are associated with other serious non-cancerous conditions also. As it was recently revealed that using NSAIDs increases the risk of myocardial infarction (155). Among the medications examined were Celecoxib, ibuprofen, diclofenac, naproxen, and rofecoxib (156). According to a study, many NSAID users reported gastrointestinal side effects ranging from nausea, slight pain, and dyspeptic symptoms to serious problems like bleeding, peptic ulcer rupture, and intestinal blockage (157). Peptic ulcer illness in the past, age, and concurrent aspirin usage are all significant risk factors for developing GI side effects in NSAID users (158, 159). NSAIDs are known for having substantial renal side effects, which in extreme situations might result in renal failure, in addition to cardiovascular and gastrointestinal problems (160). A higher risk has been noted in previous research for acute renal failure. Thus, the use of NSAIDs in the treatment and prevention of cancer must be carefully evaluated and there must also be a balance between the risks and the benefits (5).

7.3. Future perspectives

The number of studies on CRC chemoprevention has grown. Although NSAIDs have shown the most promise, only those with a greater risk of CRC predisposition syndromes, such as Lynch syndrome or FAP, have been advised to take them as chemopreventive medicines (161). The ideal CRC chemoprevention drug is elusive for the majority of patients. Finding new colonic neoplastic pathways that can be targeted as well as developing drug combinations that maximize efficacy and reduce toxicity are obstacles to CRC chemoprevention. It’s crucial to establish if more typical intermediate endpoints, like ACF or adenomas, may be employed given the generally low incidence of CRC in populations at average risk. Identifying subgroups based on genetic characteristics that influence treatment response, a history of polyps, and the subtype of a polyp is vital to determine which subgroups are most likely to benefit from chemoprevention drugs with the lowest degree of risk. CRC chemoprevention research must overcome obstacles including the necessity for funds to finance lengthy trials that enlist lots of participants and the requirement to validate results in various ethnic groups and geographical regions. Since many possible chemoprevention medicines are sold as over-the-counter drugs or dietary supplements, it is crucial to get reliable data on risk since their widespread usage might skew study results. It seems doubtful that CRC screening will ever be replaced as the main form of prevention by chemoprevention. The ability to prove the effectiveness of chemoprevention techniques in clinical trials will become more challenging as screening rates rise and CRC incidence and death decline (162, 163). Therefore, studies in groups who regularly receive CRC screening will need to show a stronger protective impact to significantly support chemoprevention in addition to screening. In conclusion, a chemopreventive drug that is generally effective, safe, affordable, accessible, and simple to use is appropriate for CRC. The promise of lowering CRC risk and lowering its morbidity and mortality makes CRC chemoprevention an activity worth continuing to pursue, even if it is difficult to discover a chemoprevention medication that complies with these requirements.

8. Conclusion

CRC being the second leading cause of cancer death globally is a major concern among the WHO (World Health Organization). Its preventive measures and treatments have become one of the challenging issues in the public health sector. CRC has been regarded as a sporadic and hereditary disease caused due to accumulation of genetic and epigenetic abnormalities in epithelial cells of the large intestine. It comprises of several modifiable (diet, alcohol, obesity, exercise) and non-modifiable risk factors such as age, genes, family history, etc. Several biomarkers such as KRAS, a major CRC biomarker, help in the early detection of colorectal cancer in patients. With the advent of technology and biological, physiological, and statistical constraints of endogenous biomarkers unavoidable need for the development of synthetic biomarkers in cancer sectors became a priority. Hence, several vector-based, mammalian cell-based, and bacterial cell-based synthetic biomarkers have been employed for the early detection of CRC on the basis of their advantages. Furthermore, among the various invasive techniques, colonoscopy is the most preferred method for early detection of CRC due to its better sensitivity-95% and specificity- 98% whereas sigmoidoscopy is more cost-efficient as compared to the expensive colonoscopic procedure. However, due to better specificity, colonoscopy is the most preferred procedure followed by sigmoidoscopy. Apart from this several non-invasive analytical methods based on DNA–RNA, protein, and metabolites found in a patient’s breath, blood, urine, and stool can be detected by utilizing genomic and mutation analytical techniques.

Chemoprevention techniques may help to further lower the incidence and mortality of CRC. Chemoprevention medications can be used for both low- and high-risk populations, as well as to stop colorectal cancer from returning following treatment. Aspirin, non-aspirin non-steroidal anti-inflammatory medications, statins, medicines that target metabolic pathways, vitamins, and minerals are examples of CRC chemoprevention treatments that have been explored (164).

NSAIDs are powerful anti-inflammatory, antipyretic and analgesic drugs having a chemopreventive impact on gastrointestinal malignancies, especially CRC, whereas long-term use of NSAIDs has also been linked to renal illness, myocardial infarction, gastrointestinal illness etc. Several NSAIDs, especially aspirin lower the risk and death from several malignancies, which is significant evidence that connects inflammation and cancer. The primary anticancer action of NSAIDs is assumed to be a COX-2 inhibition-mediated suppression of prostaglandin E2 production, which reduces tumor cell proliferation, and angiogenesis, and enhances apoptosis. Numerous studies have been conducted on the relationship between the expression of COX and colorectal cancer potential impact of NSAIDs-chemo-preventive drugs. It has been noted that statins and NSAIDs together show the synergistic effect as anticarcinogenic drugs in several in vitro and in vivo preclinical investigations, and this has drawn significant interest in examining their potential collaborative impact in cancer chemoprevention and combating the problems associated with the use of NSAIDs. This synergistic effect of combinational use of drugs proves to be beneficial in terms of reduced dosage and duration which is a potential technique for improving cancer prevention effectiveness.

Author contributions

GR and NAK played a role in designing the study as well as drafted the review paper. NAK, DE, AR, Tanzeelah, HM, HA, AR, and MSU did the writing part. AB, MAK, and WH helped in the revision. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Duarte Mendes, A, Vicente, R, Vitorino, M, Silva, M, and Alpuim Costa, D. Modulation of tumor environment in colorectal cancer – could gut microbiota be a key player? Frontiers in Gastroenterology. (2022) 1:23. doi: 10.3389/FGSTR.2022.1021050

CrossRef Full Text | Google Scholar

2. Lundqvist, E, Myrberg, IH, Boman, SE, Saraste, D, Weibull, CE, Landerholm, K, et al. Autoimmune and metabolic diseases and the risk of early-onset colorectal cancer, a Nationwide nested case–control study. Cancer. (2023) 15:688. doi: 10.3390/cancers15030688

CrossRef Full Text | Google Scholar

3. Knowlton, CA, Mackay, MK, Speer, TW, Vera, RB, Arthur, DW, Wazer, DE, et al. Cancer colon. Encyclo Radiat Oncol. (2013):77–7. doi: 10.1007/978-3-540-85516-3_1047/COVER

CrossRef Full Text | Google Scholar

4. Bien, SA, Su, YR, Conti, DV, Harrison, TA, Qu, C, Guo, X, et al. Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. Hum Genet. (2019) 138:307–26. doi: 10.1007/s00439-019-02030-8

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Alvarez-Gonzalez, MA, Pantaleon, MA, Flores-Le Roux, JA, Zaffalon, D, Amorós, J, Bessa, X, et al. Randomized clinical trial: a normocaloric low-fiber diet the day before colonoscopy is the most effective approach to bowel preparation in colorectal cancer screening colonoscopy. Dis Colon Rectum. (2019) 62:491–7. doi: 10.1097/DCR.0000000000001305

CrossRef Full Text | Google Scholar

6. Aronson, JK, and Ferner, RE. Biomarkers—A General Review. Curr Protoc Pharmacol. (2017) 76:9.23.1–9.23.17. doi: 10.1002/cpph.19

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Businello, G, Parente, P, Mastracci, L, Pennelli, G, Traverso, G, Milione, M, et al. The pathologic and molecular landscape of esophageal squamous cell carcinogenesis. Cancer. (2020) 12:2160. doi: 10.3390/CANCERS12082160

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Ogunwobi, OO, Mahmood, F, and Akingboye, A. Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci. (2020) 21:5311. doi: 10.3390/ijms21155311

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Shaukat, A, and Levin, TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. (2022) 19:521–31. doi: 10.1038/s41575-022-00612-y

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Shimozaki, K, Hirata, K, Horie, S, Chida, A, Tsugaru, K, Hayashi, Y, et al. The entire intestinal tract surveillance using capsule endoscopy after immune checkpoint inhibitor administration: a prospective observational study. Diagnostics. (2021) 11:543. doi: 10.3390/diagnostics11030543

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Liang, PS, and Dominitz, JA. Colorectal cancer screening: is colonoscopy the best option? Med Clin North Am. (2019) 103:111–23. doi: 10.1016/j.mcna.2018.08.010

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Iannone, A, Losurdo, G, Pricci, M, Girardi, B, Massaro, A, Principi, M, et al. Stool investigations for colorectal cancer screening: from occult blood test to DNA analysis. J Gastrointest Cancer. (2016) 47:143–51. doi: 10.1007/s12029-016-9810-z

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Hoffman, RM, Levy, BT, and Allison, JE. Rising use of multitarget stool DNA testing for colorectal cancer. JAMA Netw Open. (2021) 4:e2122328–8. doi: 10.1001/jamanetworkopen.2021.22328

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Donegan, C, Hughes, AE, and Lee, SJC. Colorectal cancer incidence, inequalities, and prevention priorities in urban Texas: surveillance study with the “surveil” software package. JMIR Public Health Surveill. (2022) 8:e34589. doi: 10.2196/34589

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Seijo, LM, Peled, N, Ajona, D, Boeri, M, Field, JK, Sozzi, G, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol. (2019) 14:343–57. doi: 10.1016/j.jtho.2018.11.023

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Wang, YC, Tian, ZB, and Tang, XQ. Bioinformatics screening of biomarkers related to liver cancer. BMC Bioinform. (2021) 22:1–11. doi: 10.1186/S12859-021-04411-1/TABLES/2

CrossRef Full Text | Google Scholar

17. Matsuoka, T, and Yashiro, M. Biomarkers of gastric cancer: current topics and future perspective. World J Gastroenterol. (2018) 24:2818–32. doi: 10.3748/WJG.V24.I26.2818

CrossRef Full Text | Google Scholar

18. Lech, G, Słotwiński, R, Słodkowski, M, and Krasnodębski, IW. Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J Gastroenterol. (2016) 22:1745–55. doi: 10.3748/wjg.v22.i5.1745

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Giampaolino, P, Foreste, V, Della Corte, L, di Filippo, C, Iorio, G, and Bifulco, G. Role of biomarkers for early detection of ovarian cancer recurrence. Gland Surg. (2020) 9:1102–11. doi: 10.21037/gs-20-544

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Filella, X, Fernández-Galán, E, Fernández Bonifacio, R, and Foj, L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med. (2018) Volume 11:83–94. doi: 10.2147/PGPM.S136026

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Sukumar, J, Gast, K, Quiroga, D, Lustberg, M, and Williams, N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. (2021) 21:135–48. doi: 10.1080/14737140.2021.1840984

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Li, WC, Lee, PL, Chou, IC, Chang, WJ, Lin, SC, and Chang, KW. Molecular and cellular cues of diet-associated oral carcinogenesis--with an emphasis on areca-nut-induced oral cancer development. J Oral Pathol Med. (2015) 44:167–77. doi: 10.1111/jop.12171

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Eng, VA, David, SP, Li, S, Ally, MS, Stefanick, M, and Tang, JY. The association between cigarette smoking, cancer screening, and cancer stage: a prospective study of the women’s health initiative observational cohort. BMJ Open. (2020) 10:e037945. doi: 10.1136/bmjopen-2020-037945

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Jemal, A, Ward, EM, Johnson, CJ, Cronin, KA, Ma, J, Ryerson, AB, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. (2017) 109:djx030. doi: 10.1093/JNCI/DJX030

CrossRef Full Text | Google Scholar

25. Cronin, KA, Lake, AJ, Scott, S, Sherman, RL, Noone, AM, Howlader, N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. (2018) 124:2785–800. doi: 10.1002/cncr.31551

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Meyer, B, and Are, C. Current status and future directions in colorectal cancer. Indian J Surg Oncol. (2018) 9:440. doi: 10.1007/s13193-017-0711-9

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Botteri, E, Borroni, E, Sloan, EK, Bagnardi, V, Bosetti, C, Peveri, G, et al. Smoking and colorectal cancer risk, overall and by molecular subtypes: a meta-analysis. Am J Gastroenterol. (2020) 115:1940–9. doi: 10.14309/ajg.0000000000000803

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Figueiredo, JC, Crockett, SD, Snover, DC, Morris, CB, McKeown-Eyssen, G, Sandler, RS, et al. Smoking-associated risks of conventional adenomas and serrated polyps in the colorectum. Cancer Causes Control. (2015) 26:377–86. doi: 10.1007/s10552-014-0513-0

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Olsen, M, Ghannad, M, Lok, C, and Bossuyt, PM. Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review. Clin Chem Lab Med. (2019) 58:3–10. doi: 10.1515/cclm-2019-0038

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Kuchenbaecker, KB, Hopper, JL, Barnes, DR, Phillips, K-A, Mooij, TM, Roos-Blom, M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. (2017) 317:2402–16. doi: 10.1001/JAMA.2017.7112

CrossRef Full Text | Google Scholar

31. Fenton, JJ, Weyrich, MS, Durbin, S, Liu, Y, Bang, H, and Melnikow, J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA. (2018) 319:1914–31. doi: 10.1001/JAMA.2018.3712

CrossRef Full Text | Google Scholar

32. Zargar, A, Miroliaee, A, Ahmadi Gooraji, S, and Hajaghamohammadi, A. Determination of effective factors on survival of GI cancers: results of five years follow up in Iranian population. Global J Health Sci. (2016) 8:256–66. doi: 10.5539/GJHS.V8N6P256

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Allegra, CJ, Rumble, RB, Hamilton, SR, Mangu, PB, Roach, N, Hantel, A, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol. (2016) 34:179–85. doi: 10.1200/JCO.2015.63.9674

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Locker, GY, Hamilton, S, Harris, J, Jessup, JM, Kemeny, N, Macdonald, JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. (2006) 24:5313–27. doi: 10.1200/JCO.2006.08.2644

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Lim, E, Palmieri, C, and Tilley, WD. Renewed interest in the progesterone receptor in breast cancer. Br J Cancer. (2016) 115:909–11. doi: 10.1038/bjc.2016.303

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Bang, YJ, van Cutsem, E, Feyereislova, A, Chung, HC, Shen, L, Sawaki, A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. (2010) 376:687–97. doi: 10.1016/S0140-6736(10)61121-X

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Acharya, A, Markar, SR, Matar, M, Ni, M, and Hanna, GB. Use of tumor markers in gastrointestinal cancers: surgeon perceptions and cost-benefit trade-off analysis. Ann Surg Oncol. (2017) 24:1165–73. doi: 10.1245/s10434-016-5717-y

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Pedrazzoli, P, Rosti, G, Soresini, E, Ciani, S, and Secondino, S. Serum tumour markers in germ cell tumours: from diagnosis to cure. Crit Rev Oncol Hematol. (2021) 159:103224. doi: 10.1016/j.critrevonc.2021.103224

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Kabel, AM. Tumor markers of breast cancer: new prospectives. J Oncol Sci. (2017) 3:5–11. doi: 10.1016/j.jons.2017.01.001

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Kwong, GA, Ghosh, S, Gamboa, L, Patriotis, C, Srivastava, S, and Bhatia, SN. Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat Rev Cancer. (2021) 21:655–68. doi: 10.1038/s41568-021-00389-3

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Zhang, XJ, Hu, LY, Hu, Y, Yang, XT, Tang, YY, Tang, YY, et al. Tumor-penetrating hierarchically structured Nanomarker for imaging-guided urinary monitoring of cancer. ACS Sens. (2020) 5:1567–72. doi: 10.1021/acssensors.9b02194

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Lopez-Giacoman, S, and Madero, M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol. (2015) 4:57–73. doi: 10.5527/wjn.v4.i1.57

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Kobayashi, K, Kawaguchi, Y, Kobayashi, Y, Matsumura, M, Ishizawa, T, Akamatsu, N, et al. Identification of liver lesions using fluorescence imaging: comparison of methods for administering indocyanine green. HPB. (2021) 23:262–9. doi: 10.1016/j.hpb.2020.06.006

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Khan, NA, Hussain, M, Rahman, AU, Farooqui, WA, Rasheed, A, and Memon, AS. Dietary practices, addictive behavior and bowel habits and risk of early onset colorectal cancer: a case control study. Asian Pac J Cancer Prev. (2015) 16:7967–73. doi: 10.7314/APJCP.2015.16.17.7967

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Eibl, RH, and Schneemann, M. Cell-free DNA as a biomarker in cancer. Extracell Vesicles Circ Nucl Acids. (2022) 3:178–98. doi: 10.20517/evcna.2022.20

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Li, H, Zhang, H, Lu, G, Li, Q, Gu, J, Song, Y, et al. Mechanism analysis of colorectal cancer according to the microRNA expression profile. Oncol Lett. (2016) 12:2329. doi: 10.3892/ol.2016.5027

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Song, L, and Li, Y. SEPT9: a specific circulating biomarker for colorectal cancer. Adv Clin Chem. (2015) 72:171–204. doi: 10.1016/BS.ACC.2015.07.004

CrossRef Full Text | Google Scholar

48. Dong, L, Lin, W, Qi, P, Xu, MD, Wu, X, Ni, S, et al. Circulating long RNAs in serum extracellular vesicles: their characterization and potential application as biomarkers for diagnosis of colorectal cancer. Cancer Epidemiol Biomark Prev. (2016) 25:1158–66. doi: 10.1158/1055-9965.EPI-16-0006

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Wang, Y, Li, Z, Li, W, Liu, S, and Han, B. Methylation of promoter region of CDX2 gene in colorectal cancer. Oncol Lett. (2016) 12:3229. doi: 10.3892/ol.2016.5109

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Mezheyeuski, A, Ponten, F, Edqvist, PH, Sundström, M, Thunberg, U, Qvortrup, C, et al. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncol. (2020) 59:284–90. doi: 10.1080/0284186X.2019.1691258

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Issa, IA, and NouredDine, M. Colorectal cancer screening: An updated review of the available options. World J Gastroenterol. (2017) 23:5086. doi: 10.3748/wjg.v23.i28.5086

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Dettling, DE, Kwok, E, Quach, L, Datt, A, Degenhardt, JD, Panchal, A, et al. Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186. J Immunother Cancer. (2022) 10:e004336. doi: 10.1136/jitc-2021-004336

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Lopes, N, Bergsland, C, Bruun, J, Bjørnslett, M, Vieira, AF, Mesquita, P, et al. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer. (2020) 23:811–23. doi: 10.1007/s10120-020-01064-6

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Wong, K-F, Liu, AM, Hong, W, Xu, Z, Luk, JM, Wong, K-F, et al. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget. (2016) 7:77683–95. doi: 10.18632/oncotarget.12760

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Jia, H, and Wang, Z. Telomere length as a prognostic factor for overall survival in colorectal cancer patients. Cell Physiol Biochem. (2016) 38:122–8. doi: 10.1159/000438614

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Hultcrantz, R. Aspects of colorectal cancer screening, methods, age and gender. J Intern Med. (2021) 289:493–507. doi: 10.1111/joim.13171

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Kim, S, Wong, P, and Coulombe, PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature. (2006) 441:362–5. doi: 10.1038/nature04659

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Sheng, J, Sun, H, Yu, F-B, Li, B, Zhang, Y, Zhu, Y-T, et al. The role of Cyclooxygenase-2 in colorectal cancer. Int J Med Sci. (2020) 2020:1095–101. doi: 10.7150/ijms.44439

CrossRef Full Text | Google Scholar

59. Rao, X, Wang, J, Song, HM, Deng, B, and Li, JG. KRT15 overexpression predicts poor prognosis in colorectal cancer. Neoplasma. (2020) 67:410–4. doi: 10.4149/neo_2019_190531N475

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Dawson, H, and Lugli, A. Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med. (2015) 2:11. doi: 10.3389/fmed.2015.00011

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Li, J, Hao, Q, Cao, W, Vadgama, J, and Wu, Y. Celecoxib in breast cancer prevention and therapy. Cancer Manag Res. (2018) 10:4653–67. doi: 10.2147/CMAR.S178567

CrossRef Full Text | Google Scholar

62. Binefa, G, Rodríguez-Moranta, F, Teule, À, and Medina-Hayas, M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. (2014) 20:6786–808. doi: 10.3748/wjg.v20.i22.6786

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Ma, L, Qin, G, Gai, F, Jiang, Y, Huang, Z, Yang, H, et al. A novel method for early detection of colorectal cancer based on detection of methylation of two fragments of syndecan-2 (SDC2) in stool DNA. BMC Gastroenterol. (2022) 22:1–10. doi: 10.1186/S12876-022-02264-3/TABLES/5

CrossRef Full Text | Google Scholar

64. Oh, T, Kim, N, Moon, Y, Kim, MS, Hoehn, BD, Park, CH, et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn. (2013) 15:498–507. doi: 10.1016/j.jmoldx.2013.03.004

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Tuohy, TMF, Rowe, KG, Mineau, GP, Pimentel, R, Burt, RW, and Samadder, NJ. Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah. Cancer. (2014) 120:35–42. doi: 10.1002/cncr.28227

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Itatani, Y, Kawada, K, and Sakai, Y. Treatment of elderly patients with colorectal cancer. Biomed Res Int. (2018) 2018:2176056. doi: 10.1155/2018/2176056

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Schottinger, JE, Jensen, CD, Ghai, NR, Chubak J, Lee, JK, Kamineni, A, et al. Association of physician adenoma detection rates with postcolonoscopy colorectal cancer. Jama. (2022) 327:2114–22.

Google Scholar

68. Corley, DA, Jensen, CD, Marks, AR, Zhao, WK, Lee, JK, Doubeni, CA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. (2014) 370:1298–306. doi: 10.1056/NEJMoa1309086

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Kaminski, MF, Regula, J, Kraszewska, E, Polkowski, M, Wojciechowska, U, Didkowska, J, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. (2010) 362:1795–803. doi: 10.1056/NEJMoa0907667

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Carter, JV, Roberts, HL, Pan, J, Rice, JD, Burton, JF, Galbraith, NJ, et al. A highly predictive model for diagnosis of colorectal neoplasms using plasma microRNA: improving specificity and sensitivity. Annals of Surgery. (2016) 264:575.

Google Scholar

71. Gupta, S. Screening for colorectal cancer. Hematol Oncol Clin North Am. (2022) 36:393–414. doi: 10.1016/j.hoc.2022.02.001

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Imperiale, TF, Ransohoff, DF, Itzkowitz, SH, Levin, TR, Lavin, P, Lidgard, GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. (2014) 370:1287–97. doi: 10.1056/NEJMoa1311194

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Bromer, MQ, and Weinberg, DS. Screening for colorectal cancer - now and the near future. Semin Oncol. (2005) 32:3–10. doi: 10.1053/j.seminoncol.2004.09.031

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Maida, M, Macaluso, FS, Ianiro, G, Mangiola, F, Sinagra, E, Hold, G, et al. Screening of colorectal cancer: present and future. Expert Rev Anticancer Ther. (2017) 17:1131–46. doi: 10.1080/14737140.2017.1392243

PubMed Abstract | CrossRef Full Text | Google Scholar

75. Hassan, C, Antonelli, G, Dumonceau, JM, Regula, J, Bretthauer, M, Chaussade, S, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2020. Endoscopy. (2020) 52:687–700. doi: 10.1055/a-1185-3109

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Zygulska, AL, and Pierzchalski, P. Novel diagnostic biomarkers in colorectal cancer. Int J Mol Sci. (2022) 23:852. doi: 10.3390/ijms23020852

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Lin, JS, Perdue, LA, Henrikson, NB, Bean, SI, and Blasi, PR. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. (2021) 325:1978–98. doi: 10.1001/JAMA.2021.4417

CrossRef Full Text | Google Scholar

78. Wang, Y, Chen, PM, Liu, R, and bin,. Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. World J Gastrointest Oncol. (2018) 10:15. doi: 10.4251/wjgo.v10.i1.15

PubMed Abstract | CrossRef Full Text | Google Scholar

79. Daniel, C. L. (2013). Predictors of colorectal cancer surveillance among survivors of childhood cancer at high risk for subsequent colorectal malignancies. The University of Alabama at Birmingham.

Google Scholar

80. Song, L, Jia, J, Peng, X, Xiao, W, and Li, Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis. Sci Rep. (2017) 7:1–12. doi: 10.1038/s41598-017-03321-8

CrossRef Full Text | Google Scholar

81. Sawicki, T, Ruszkowska, M, Danielewicz, A, Niedźwiedzka, E, Arłukowicz, T, and Przybyłowicz, KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers. (2021) 13:2025. doi: 10.3390/cancers13092025

PubMed Abstract | CrossRef Full Text | Google Scholar

82. Malik, P. A novel multitarget stool DNA test for colorectal cancer screening. Postgrad Med. (2016) 128:268–72. doi: 10.1080/00325481.2016.1135035

PubMed Abstract | CrossRef Full Text | Google Scholar

83. Guinney, J, Dienstmann, R, Wang, X, de Reyniès, A, Schlicker, A, Soneson, C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. (2015) 21:1350–6. doi: 10.1038/nm.3967

PubMed Abstract | CrossRef Full Text | Google Scholar

84. Alorda-Clara, M, Torrens-Mas, M, Morla-Barcelo, PM, Martinez-Bernabe, T, Sastre-Serra, J, Roca, P, et al. Use of omics technologies for the detection of colorectal cancer biomarkers. Cancers. (2022) 14:817. doi: 10.3390/cancers14030817

PubMed Abstract | CrossRef Full Text | Google Scholar

85. Jin, J. Nonsteroidal anti-inflammatory drugs. JAMA. (2015) 314:1084–4. doi: 10.1001/JAMA.2015.9936

CrossRef Full Text | Google Scholar

86. Piazuelo, E, and Lanas, A. NSAIDS and gastrointestinal cancer. Prostaglandins Other Lipid Mediat. (2015) 120:91–6. doi: 10.1016/j.prostaglandins.2015.06.001

PubMed Abstract | CrossRef Full Text | Google Scholar

87. Iavecchia, L, Cereza García, G, Sabaté Gallego, M, Vidal Guitart, X, Ramos Terrades, N, de la Torre, J, et al. Drug-related acute renal failure in hospitalised patients. Nefrología. (2015) 35:523–32. doi: 10.1016/j.nefroe.2016.01.001

PubMed Abstract | CrossRef Full Text | Google Scholar

88. Sheng, J, Sun, H, Yu, FB, Li, B, Zhang, Y, Zhu, YT. The role of cyclooxygenase-2 in colorectal cancer. Int.l J. Med. Sci. (2020) 17:1095.

Google Scholar

89. Rouzer, CA, and Marnett, LJ. Cyclooxygenases: structural and functional insights. J Lipid Res. (2009) 50:S29–34. doi: 10.1194/jlr.R800042-JLR200

PubMed Abstract | CrossRef Full Text | Google Scholar

90. Bäumler, P, Zhang, W, Stübinger, T, and Irnich, D. Acupuncture-related adverse events: systematic review and meta-analyses of prospective clinical studies. BMJ Open. (2021) 11:e045961. doi: 10.1136/bmjopen-2020-045961

PubMed Abstract | CrossRef Full Text | Google Scholar

91. McEvoy, L, Carr, DF, and Pirmohamed, M. Pharmacogenomics of NSAID-induced upper gastrointestinal toxicity. Front Pharmacol. (2021) 12:684162.

Google Scholar

92. Zhang, Y, Pan, KF, Zhang, L, Ma, JL, Zhou, T, Li, J, et al. Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. Carcinogenesis. (2015) 36:1572–9. doi: 10.1093/carcin/bgv147

PubMed Abstract | CrossRef Full Text | Google Scholar

93. Kolawole, OR, and Kashfi, K. NSAIDs and cancer resolution: new paradigms beyond cyclooxygenase. Int J Mol Sci. (2022) 23:1432. doi: 10.3390/ijms23031432

PubMed Abstract | CrossRef Full Text | Google Scholar

94. Medzhitov, R. Origin and physiological roles of inflammation. Nature. (2008) 454:428–35. doi: 10.1038/nature07201

PubMed Abstract | CrossRef Full Text | Google Scholar

95. Kune, GA, Kune, S, and Watson, LF. Colorectal cancer risk, chronic illnesses, operations and medications: case–control results from the Melbourne colorectal cancer study. Int J Epidemiol. (2007) 36:951–7. doi: 10.1093/ije/dym193

PubMed Abstract | CrossRef Full Text | Google Scholar

96. Ohara, K, Takahara, M, Kumai, T, Yamashina, M, Kishibe, K, Katada, A, and Hayashi, T. Treatment outcomes of alternating chemoradiotherapy for nasopharyngeal carcinoma: a single-center safety and efficacy study. Brazilian J Otorhinolaryngol (2022) doi: 10.1016/j.bjorl.2022.12.004 [Epub ahead of print].

PubMed Abstract | CrossRef Full Text | Google Scholar

97. Siegfried, G, Descarpentrie, J, Evrard, S, and Khatib, AM. Proprotein convertases: key players in inflammation-related malignancies and metastasis. Cancer Lett. (2020) 473:50–61. doi: 10.1016/j.canlet.2019.12.027

PubMed Abstract | CrossRef Full Text | Google Scholar

98. Hefetz-Sela, S, Stein, I, and Pikarsky, E. Restoring inflammatory balance as a potential preventive strategy for inflammation induced cancer. Oncoimmunology. (2015) 4:e1039764. doi: 10.1080/2162402X.2015.1039764

CrossRef Full Text | Google Scholar

99. Sankaranarayanan, R, Kumar, DR, Altinoz, MA, and Bhat, GJ. Mechanisms of colorectal cancer prevention by aspirin-a literature review and perspective on the role of COX-dependent and -independent pathways. Int J Mol Sci. (2020) 21:1–18. doi: 10.3390/IJMS21239018

CrossRef Full Text | Google Scholar

100. Chen, J, and Stark, LA. Aspirin prevention of colorectal cancer: focus on NF-κB Signalling and the nucleolus. Biomedicine. (2017) 5:43. doi: 10.3390/biomedicines5030043

PubMed Abstract | CrossRef Full Text | Google Scholar

101. Liu, B, Qu, L, and Yan, S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. (2015) 15:1–6. doi: 10.1186/S12935-015-0260-7/TABLES/1

CrossRef Full Text | Google Scholar

102. Pang, LY, Hurst, EA, and Argyle, DJ. Cyclooxygenase-2: a role in cancer stem cell survival and repopulation of cancer cells during therapy. Stem Cells Int. (2016) 2016:2048731. doi: 10.1155/2016/2048731

PubMed Abstract | CrossRef Full Text | Google Scholar

103. Pannunzio, A, and Coluccia, M. Cyclooxygenase-1 (COX-1) and COX-1 inhibitors in cancer: a review of oncology and medicinal chemistry literature. Pharmaceuticals. (2018) 11:101. doi: 10.3390/ph11040101

PubMed Abstract | CrossRef Full Text | Google Scholar

104. Bruno, A, Contursi, A, Tacconelli, S, Sacco, A, Hofling, U, Mucci, M, et al. The specific deletion of cyclooxygenase-1 in megakaryocytes/platelets reduces intestinal polyposis in ApcMin/+ mice. Pharmacol Res. (2022) 185:106506. doi: 10.1016/j.phrs.2022.106506

PubMed Abstract | CrossRef Full Text | Google Scholar

105. Rouzer, CA, and Marnett, LJ. Structural and chemical biology of the interaction of cyclooxygenase with substrates and non-steroidal anti-inflammatory drugs. Chem Rev. (2020) 120:7592–641. doi: 10.1021/acs.chemrev.0c00215

PubMed Abstract | CrossRef Full Text | Google Scholar

106. Maniewska, J, and Jeżewska, D. Non-steroidal anti-inflammatory drugs in colorectal cancer chemoprevention. Cancer. (2021) 13:594. doi: 10.3390/cancers13040594

PubMed Abstract | CrossRef Full Text | Google Scholar

107. Olkinuora, AP, Peltomäki, PT, Aaltonen, LA, and Rajamäki, K. From APC to the genetics of hereditary and familial colon cancer syndromes. Hum Mol Genet. (2021) 30:R206–24. doi: 10.1093/hmg/ddab208

PubMed Abstract | CrossRef Full Text | Google Scholar

108. Cho, M, Gwak, J, Park, S, Won, J, Kim, DE, Sung, SY, et al. Diclofenac attenuates Wnt/β-catenin signaling in colon cancer cells by activation of NF-κB. FEBS Lett. (2005) 579:4213–8. doi: 10.1016/j.febslet.2005.06.049

PubMed Abstract | CrossRef Full Text | Google Scholar

109. PDQ Cancer Genetics Editorial Board Genetics of colorectal cancer (PDQ®): health professional version. PDQ Cancer Information Summaries. (2002). http://www.ncbi.nlm.nih.gov/pubmed/26389505 [Accessed January 22, 2023]

Google Scholar

110. Zaman, FY, Orchard, SG, Haydon, A, and Zalcberg, JR. Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies. Br J Cancer. (2022) 127:1735–43. doi: 10.1038/s41416-022-01882-8

PubMed Abstract | CrossRef Full Text | Google Scholar

111. Marley, AR, and Nan, H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. (2016) 7:105.

PubMed Abstract | Google Scholar

112. Kanth, P, Grimmett, J, Champine, M, Burt, R, and Samadder, NJ. Hereditary colorectal polyposis and cancer syndromes: a primer on diagnosis and management. Am J Gastroenterol. (2017) 112:1509–25. doi: 10.1038/ajg.2017.212

PubMed Abstract | CrossRef Full Text | Google Scholar

113. Santoro, A, Bufo, P, Russo, G, Cagiano, S, Papagerakis, S, Bucci, P, et al. Expression and clinical implication of cyclooxygenase-2 and E-cadherin in oral squamous cell carcinomas. Cancer Biol Ther. (2020) 21:667–74. doi: 10.1080/15384047.2015.1071741

CrossRef Full Text | Google Scholar

114. Jara-Gutiérrez, Á, and Baladrón, V. The role of prostaglandins in different types of cancer. Cells. (2021) 10:1487. doi: 10.3390/cells10061487

PubMed Abstract | CrossRef Full Text | Google Scholar

115. Misron, NA, Looi, LM, and Nik Mustapha, NR. Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression. Asian Pac J Cancer Prev. (2015) 16:1553–8. doi: 10.7314/APJCP.2015.16.4.1553

PubMed Abstract | CrossRef Full Text | Google Scholar

116. Stiller, CO, and Hjemdahl, P. Lessons from 20 years with COX-2 inhibitors: importance of dose–response considerations and fair play in comparative trials. J Intern Med. (2022) 292:557–74. doi: 10.1111/joim.13505

PubMed Abstract | CrossRef Full Text | Google Scholar

117. Warner, TD, Giuliano, F, Vojnovic, I, Bukasa, A, Mitchell, JA, and Vane, JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. (1999) 96:7563–8. doi: 10.1073/pnas.96.13.7563

PubMed Abstract | CrossRef Full Text | Google Scholar

118. Hamoya, T, Fujii, G, Miyamoto, S, Takahashi, M, Totsuka, Y, Wakabayashi, K, et al. Effects of NSAIDs on the risk factors of colorectal cancer: a mini review. Genes Environ. (2016) 38:1–7. doi: 10.1186/S41021-016-0033-0/TABLES/2

CrossRef Full Text | Google Scholar

119. Smith, ML, Hawcroft, G, and Hull, MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer. (2000) 36:664–74. doi: 10.1016/S0959-8049(99)00333-0

PubMed Abstract | CrossRef Full Text | Google Scholar

120. Faruk, M, Ibrahim, S, Aminu, SM, Adamu, A, Abdullahi, A, Suleiman, AM, et al. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin. PLoS One. (2021) 16:e0245581. doi: 10.1371/journal.pone.0245581

PubMed Abstract | CrossRef Full Text | Google Scholar

121. Song, L, Liu, D, Zhao, Y, He, J, Kang, H, Dai, Z, et al. Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem Biophys Res Commun. (2015) 464:705–10. doi: 10.1016/j.bbrc.2015.07.004

PubMed Abstract | CrossRef Full Text | Google Scholar

122. Li, X, Gao, L, Cui, Q, Gary, BD, Dyess, DL, Taylor, W, et al. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene. (2012) 31:4979–86. doi: 10.1038/onc.2011.655

PubMed Abstract | CrossRef Full Text | Google Scholar

123. Loveridge, CJ, MacDonald, ADH, Thoms, HC, Dunlop, MG, and Stark, LA. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-κB. Oncogene. (2008) 27:2648–55. doi: 10.1038/sj.onc.1210891

PubMed Abstract | CrossRef Full Text | Google Scholar

124. Bienz, M, and Clevers, H. Linking colorectal cancer to Wnt signaling. Cells. (2000) 103:311–20. doi: 10.1016/S0092-8674(00)00122-7

PubMed Abstract | CrossRef Full Text | Google Scholar

125. Piazza, GA, Ward, A, Chen, X, Maxuitenko, Y, Coley, A, Aboelella, NS, et al. PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. Drug Discov Today. (2020) 25:1521–7. doi: 10.1016/j.drudis.2020.06.008

PubMed Abstract | CrossRef Full Text | Google Scholar

126. Keum, NN, and Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. (2019) 16:713–32. doi: 10.1038/s41575-019-0189-8

PubMed Abstract | CrossRef Full Text | Google Scholar

127. Fajardo, AM, and Piazza, GA. Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol. (2015) 309:G59–70. doi: 10.1152/ajpgi.00101.2014

PubMed Abstract | CrossRef Full Text | Google Scholar

128. Siegel, RL, Miller, KD, and Jemal, A. Cancer statistics, 2016. CA Cancer J Clin. (2016) 66:7–30. doi: 10.3322/caac.21332

PubMed Abstract | CrossRef Full Text | Google Scholar

129. Wesselink, E, van Baar, H, van Zutphen, M, Tibosch, M, Kouwenhoven, EA, Keulen, ETP, et al. Inflammation is a mediating factor in the association between lifestyle and fatigue in colorectal cancer patients. Cancers. (2020) 12:1–13. doi: 10.3390/CANCERS12123701

CrossRef Full Text | Google Scholar

130. Wong, KE, Ngai, SC, Chan, KG, Lee, LH, Goh, BH, and Chuah, LH. Curcumin nanoformulations for colorectal cancer: a review. Front Pharmacol. (2019) 10:152. doi: 10.3389/FPHAR.2019.00152/BIBTEX

CrossRef Full Text | Google Scholar

131. Chaudhary, A, Sutaria, D, Huang, Y, Wang, J, and Prabhu, S. Chemoprevention of colon cancer in a rat carcinogenesis model using a novel nanotechnology-based combined treatment system. Cancer Prev Res. (2011) 4:1655–64. doi: 10.1158/1940-6207.CAPR-11-0129

PubMed Abstract | CrossRef Full Text | Google Scholar

132. Mohammed, A, Yarla, NS, Madka, V, and Rao, CV. Clinically relevant anti-inflammatory agents for chemoprevention of colorectal cancer: new perspectives. Int J Mol Sci. (2018) 19:2332. doi: 10.3390/IJMS19082332

CrossRef Full Text | Google Scholar

133. Tsioulias, GJ, Go, MF, and Rigas, B. NSAIDs and colorectal cancer control: promise and challenges. Curr Pharmacol Rep. (2015) 1:295–301. doi: 10.1007/s40495-015-0042-x

PubMed Abstract | CrossRef Full Text | Google Scholar

134. Blais, L, Desgagné, A, and LeLorier, J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. (2000) 160:2363–8. doi: 10.1001/archinte.160.15.2363

PubMed Abstract | CrossRef Full Text | Google Scholar

135. Jalving, M, Koornstra, JJ, de Jong, S, de Vries, EGE, and Kleibeuker, JH. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther. (2005) 21:321–39. doi: 10.1111/j.1365-2036.2005.02335.x

PubMed Abstract | CrossRef Full Text | Google Scholar

136. Reddy, BS, Chung, XW, Kong, AN, Tin, OK, Zheng, X, Steele, VE, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res. (2006) 66:4542–6. doi: 10.1158/0008-5472.CAN-05-4428

PubMed Abstract | CrossRef Full Text | Google Scholar

137. Mollinedo, F, and Gajate, C. Lipid rafts as major platforms for signaling regulation in cancer. Adv Biol Regul. (2015) 57:130–46. doi: 10.1016/j.jbior.2014.10.003

PubMed Abstract | CrossRef Full Text | Google Scholar

138. Zhuang, L, Kim, J, Adam, RM, Solomon, KR, and Freeman, MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. (2005) 115:959–68. doi: 10.1172/JCI200519935

PubMed Abstract | CrossRef Full Text | Google Scholar

139. Sahai, E, and Marshall, CJ. RHO-GTPases and cancer. Nat Rev Cancer. (2002) 2:133–42. doi: 10.1038/nrc725

PubMed Abstract | CrossRef Full Text | Google Scholar

140. Niu, S, Ma, X, Zhang, Y, Liu, YN, Chen, X, Gong, H, et al. MicroRNA-19a and microRNA-19b promote the malignancy of clear cell renal cell carcinoma through targeting the tumor suppressor RhoB. PLoS One. (2018) 13:e0192790. doi: 10.1371/journal.pone.0192790

PubMed Abstract | CrossRef Full Text | Google Scholar

141. Grancher, A, Michel, P, di Fiore, F, and Sefrioui, D. Colorectal cancer chemoprevention: is aspirin still in the game? Cancer Biol Ther. (2022) 23:446–61. doi: 10.1080/15384047.2022.2104561

CrossRef Full Text | Google Scholar

142. Ishikawa, H, Mutoh, M, Suzuki, S, Tokudome, S, Saida, Y, Abe, T, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. (2014) 63:1755–9. doi: 10.1136/gutjnl-2013-305827

PubMed Abstract | CrossRef Full Text | Google Scholar

143. Gurpinar, E, Grizzle, WE, and Piazza, GA. NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res. (2014) 20:1104. doi: 10.1158/1078-0432.CCR-13-1573

PubMed Abstract | CrossRef Full Text | Google Scholar

144. Rothwell, PM, Cook, NR, Gaziano, JM, Price, JF, Belch, JFF, Roncaglioni, MC, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. (2018) 392:387–99. doi: 10.1016/S0140-6736(18)31133-4

PubMed Abstract | CrossRef Full Text | Google Scholar

145. Kemp Bohan, PM, Mankaney, G, Vreeland, TJ, Chick, RC, Hale, DF, Cindass, JL, et al. Chemoprevention in familial adenomatous polyposis: past, present and future. Familial Cancer. (2021) 20:23–33. doi: 10.1007/s10689-020-00189-y

PubMed Abstract | CrossRef Full Text | Google Scholar

146. Langley, RE, Burdett, S, Tierney, JF, Cafferty, F, Parmar, MKB, and Venning, G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. (2011) 105:1107–13. doi: 10.1038/bjc.2011.289

PubMed Abstract | CrossRef Full Text | Google Scholar

147. Gay, LJ, and Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. (2011) 11:123–34. doi: 10.1038/nrc3004

PubMed Abstract | CrossRef Full Text | Google Scholar

148. Xu, XR, Yousef, GM, and Ni, H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. (2018) 131:1777–89. doi: 10.1182/blood-2017-05-743187

PubMed Abstract | CrossRef Full Text | Google Scholar

149. Zelenay, S, van der Veen, AG, Böttcher, JP, Snelgrove, KJ, Rogers, N, Acton, SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cells. (2015) 162:1257–70. doi: 10.1016/j.cell.2015.08.015

PubMed Abstract | CrossRef Full Text | Google Scholar

150. Thompson, PA, Ashbeck, EL, Roe, DJ, Fales, L, Buckmeier, J, Wang, F, et al. Selenium supplementation for prevention of colorectal adenomas and risk of associated type 2 diabetes. J Natl Cancer Inst. (2016) 108:djw152. doi: 10.1093/JNCI/DJW152

CrossRef Full Text | Google Scholar

151. Umezawa, S, Higurashi, T, Komiya, Y, Arimoto, J, Horita, N, Kaneko, T, et al. Chemoprevention of colorectal cancer: past, present, and future. Cancer Sci. (2019) 110:3018–26. doi: 10.1111/cas.14149

PubMed Abstract | CrossRef Full Text | Google Scholar

152. Baron, JA, Sandler, RS, Bresalier, RS, Quan, H, Riddell, R, Lanas, A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. (2006) 131:1674–82. doi: 10.1053/j.gastro.2006.08.079

PubMed Abstract | CrossRef Full Text | Google Scholar

153. Brusselaers, N, and Lagergren, J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. (2018) 8:e021869. doi: 10.1136/bmjopen-2018-021869

PubMed Abstract | CrossRef Full Text | Google Scholar

154. Shekelle, PG, Newberry, SJ, FitzGerald, JD, Motala, A, O’Hanlon, CE, Tariq, A, et al. Management of Gout: a systematic review in support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. (2017) 166:37–51. doi: 10.7326/M16-0461

PubMed Abstract | CrossRef Full Text | Google Scholar

155. Shebl, FM, Hsing, AW, Park, Y, Hollenbeck, AR, Chu, LW, Meyer, TE, et al. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study. PLoS One. (2014) 9:e114633. doi: 10.1371/journal.pone.0114633

PubMed Abstract | CrossRef Full Text | Google Scholar

156. Shimoji, K, and Fujioka, H. Pharmacology of analgesics. In: Chronic Pain Management in General and Hospital Practice. (2021). p. 55–86.

Google Scholar

157. Itani, R, Soubra, L, Karout, S, Rahme, D, Karout, L, and Khojah, HMJ. Primary dysmenorrhea: pathophysiology, diagnosis, and treatment updates. Korean J Fam Med. (2022) 43:101. doi: 10.4082/kjfm.21.0103

PubMed Abstract | CrossRef Full Text | Google Scholar

158. Ouakrim, DA, Dashti, SG, Chau, R, Buchanan, DD, Clendenning, M, Rosty, C, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in lynch syndrome. J Natl Cancer Inst. (2015) 107:djv170. doi: 10.1093/jnci/djv170

PubMed Abstract | CrossRef Full Text | Google Scholar

159. Qaseem, A, Harris, RP, Forciea, MA, Denberg, TD, Barry, MJ, Boyd, C, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. (2017) 166:58–68. doi: 10.7326/M16-0570

PubMed Abstract | CrossRef Full Text | Google Scholar

160. Oyler, DR, Parli, SE, Bernard, AC, Chang, PK, Procter, LD, and Harned, ME. Nonopioid management of acute pain associated with trauma: focus on pharmacologic options. J Trauma Acute Care Surg. (2015) 79:475–83. doi: 10.1097/TA.0000000000000755

PubMed Abstract | CrossRef Full Text | Google Scholar

161. Testa, U, Castelli, G, and Pelosi, E. Genetic alterations of metastatic colorectal cancer. Biomedicine. (2020) 8:414. doi: 10.3390/BIOMEDICINES8100414

CrossRef Full Text | Google Scholar

162. Chubak, J, Whitlock, EP, Williams, SB, Kamineni, A, Burda, BU, Buist, DSM, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. preventive services task force. Ann Intern Med. (2016) 164:814–25. doi: 10.7326/M15-2117

PubMed Abstract | CrossRef Full Text | Google Scholar

163. Boland, PM, Yurgelun, MB, and Boland, CR. Recent progress in lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. (2018) 68:217–31. doi: 10.3322/caac.21448

CrossRef Full Text | Google Scholar

164. Drew, DA, Cao, Y, and Chan, AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. (2016) 16:173–86. doi: 10.1038/nrc.2016.4

PubMed Abstract | CrossRef Full Text | Google Scholar